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Aims 
 
Poor water-solubility is becoming the leading hurdle for pharmaceutical formulation 
scientists working on oral drug delivery leading to the development of novel formulation 
techniques. Chapter 1 gives a brief overview on the available literature on this topic. These new 
techniques often use organic solvents to transform the drug into a high-energy amorphous state 
or to produce crystalline micro- and nanoparticles. However, a major drawback of using volatile 
organic solvents is residual traces in the final product that are hard to remove. These not only 
involve toxicity issues, but might also induce phase transformation over prolonged periods of 
storage, impairing stability of the drug formulation [1]. In this regard, special guidelines have been 
issued by the European Pharmacopeia limiting the maximum allowed amount of residual solvents 
in pharmaceutical formulations [2-5].  
Taking into account these considerations, the aim of this PhD thesis is to develop and 
evaluate processing techniques for poorly water-soluble drugs without using organic solvents. 
Therefore, several approaches were evaluated. In Chapter 2, the self-emulsifying excipient 
Gelucire®44/14 and its effect on the solubility of the poorly water-soluble drug carbamazepine is 
evaluated using melt granulation and spay drying followed by compression into tablets. In 
Chapter 3, Gelucire®44/14 was evaluated as stabilizing excipient during the production of drug 
nano- and microsuspensions via mechanical impact (ball milling and ultrasonication) and as 
solubilizing matrix for melt crystallization. In Chapter 4, an aqueous coacervation technique 
comprising a molten surfactant/drug mixture was developed in view of large scale drink water 
medication for veterinary purposes. 
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1.1. Poorly Water-Soluble Drugs and the BCS Classification 
Drug development encompasses the entire process of bringing a new drug to the market 
and involves four stages: (1) drug discovery, (2) product development, (3) pre-clinical research 
and (4) clinical trials. Whereas for many decades, new active compounds were often identified via 
serendipity, nowadays high-throughput screening and combinatorial methods are applied. 
However, many of the found candidate drugs fail in clinical trial due to: adverse effects (10 %), 
toxicity (11 %), lack of efficiency (30 %) and poor bioavailability (30 %). Indeed, pharmaceutical 
industry witnesses a steady increase in poorly water-soluble drugs as lead compounds, i.e. 40 % of 
the drug molecules in development pipelines and 60 % of the drug molecules coming from 
chemical synthesis. This is of special concern for drug formulations intended for oral intake as 
good drug dissolution is a prerequisite for drug absorption and subsequently clinical response. 
 
 
Figure 1. Schematic representation of the Biopharmaceutical Classification System (BCS). 
 
Until now, comprehensive methods to predict oral absorption based on in vitro drug 
dissolution are limited, mainly due to the complexity of the processes in the gastro-intestinal tract 
and to complex pharmacokinetics. It became clear that to correlate in vitro drug dissolution and in 
vivo drug availability, one should consider drug dissolution and gastrointestinal permeability as 
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fundamental parameters controlling the rate and extent of drug absorption. For this purpose, 
Amidon and co-workers proposed the Biopharmaceutical Classification System (BCS) scheme 
that sets the basis for in vitro-in vivo correlations between drug dissolution and drug absorption. 
The BCS defines four classes of drug, as shown in Figure 1.  
Recent advances in drug formulation have introduced a variety of strategies to enhance 
the dissolution rate of poorly water-soluble drugs, and are therefore promising for the 
formulation of BCS class II drug molecules. However, before attempting any physicochemical 
approach to enhance the solubility of such drug molecules, a profound understanding of drug 
solubilization phenomena is crucial. 
 
1.2. Solubilization Phenomena 
The solubility of a compound (termed the ‘solute’) is the maximum of the solute that can 
be dissolved in a certain volume of solvent at a specific temperature, and it’s directly related to 
the solute’s hydrophilicity. The process of solubilization involves the destruction of inter-ionic or 
inter-molecular bonds in the solute trough interaction with solvent molecules. Water is a electric 
dipole and as such a good solvent for molecules that can interact via ion-dipole interaction (e.g. 
ionized molecules), Van der Waals forces, dipole-dipole interaction (e.g. molecules containing 
highly electronegative elements such as O, S, N or halogens), dipole-induced dipole interaction 
(e.g. non-polar molecules where a dipole can be induced by presence of a polar molecule) and 
hydrogen bonding (e.g. molecules containing –OH or –NH groups). Hydrogen bonding 
contributes significantly to aqueous solubilization of drugs since water can act both electron 
donor and acceptor. Solubility can be expressed in many different ways and Table 1 tries to give 
a general classification. 
For drugs that ionize in water, solubility depends in most cases not only on the intrinsic 
solubility of the non-ionized drug but also on the extent of ionization. In general, aqueous 
solubility of the ionized from is much higher than the corresponding non-ionized one. When a 
weak acid/base drug is added to an aqueous medium, it will dissolve to the extent of the intrinsic 
solubility of the non-ionized form and then ionize. According to the Hendersson-Hasselbalch 
equation, as drug ionizes more drug will dissolve to maintain a saturated solution of the non-
ionized form of the drug. 
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Table 1. Solubility defined in parts of solvent per one part of solute 
Definition 
parts of solvent required for one 
part of solute 
very soluble <1 
freely soluble 1-10 
Soluble 10-30 
sparingly soluble 30-100 
slightly soluble 100-1000 
very slightly soluble 1000-10,000 
Insoluble >10,000 
 
This process will persist until both the solubility and ionization equilibriums are achieved. 
These dynamic equilibrium processes are shown in the following equations: 
 
 weak acid drug HAsolid   HAsolution   H
++A- 
weak base drug Bsolid   Bsolution+ H
+   BH+ 
 
Saturated solutions of weak acid/weak base will contain both the ionized and the non-
ionized forms of the drug. The prevalence of either one depends on the pH of the aqueous 
medium, which this strongly influences the solubility of the drug. When the pH of the aqueous 
medium allows ionization of the weak acid/weak base, the solubility increases. Therefore, a weak 
base drug will show higher solubility at a low pH and a lower solubility at a high pH, while a weak 
acid drug will show the opposite behavior. 
Another factor influencing drug solubility is temperature. The changes in temperature 
affect solubility in two different ways. If the solubilization process requires energy then solubility 
increases at increasing temperature (endothermic dissolution process). The opposite occurs for 
exothermic dissolution processes where increasing the temperature decreases solubility. 
Other factors such as drug crystal size and the molecular weight of the drug limits its 
dissolution. The larger the molecule the more difficult is to solubilize [11]. The basis of solubility 
and solvent solubilization capacity depends on the number of interactions created between solute 
and solvent. The smaller the drug particle, the larger will be the surface available for interactions 
to take place and the higher will be its dissolution rate. Some compounds have the ability to 
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crystallize in more than one crystalline form (polymorphism), this results in different melting 
points for each polymorph and consequently different solubility [9]. 
 
1.3. Solubility enhancement techniques 
 
Based on extensive knowledge of solubility phenomena, drug formulation scientists have 
developed different formulation techniques that enhance drug solubility to increase the 
bioavailability of poorly soluble drugs. Figure 2 gives a schematic overview and below we go 
further review the different strategies used to enhance bioavailability of poorly water soluble 
drugs. 
 
 
Figure 2. Formulation techniques to improve solubility of BCS Class II Drugs 
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1.3.1. Particle size reduction 
 
Increasing the total drug surface, by particle size reduction, enhances drug saturation 
solubility and dissolution rate. Particle size reduction can be achieved through micronization and 
nanonisation.  
1.3.1.1. Micronization 
Table 2 gives an overview of the conventional methods based on mechanical force to 
disintegrate drug compounds. The principle of comminution is based in the fact that all 
crystalline materials have imperfections, and that mechanical stress will cause crack propagation. 
When mechanical stress is applied on a powder, the particles get strained. This stress-strain 
relationship is shown in Figure 3.  
 
Table 2. Type of equipment and particle size outcome to reduce drug particle size 
Method Type of equipment Approximate particle size 
(µm) 
Cutting Scissors, Shears, Cutter Mill 100-80,000 
Compression 
Roller Mill, Pestle-Mortar 50-10,000 
Impact Hammer Mill, Disintegrator 50-8000 
Attrition 
Colloidal Mill, Roller Mill, 
Pearl/Ball Mill 
1-50 
Impact and 
attrition 
Ball Mill, Fluid Energy Mill 1-2000 
 
The stress-strain curve can be divided into two distinct deformation regions, being elastic 
deformation and plastic deformation. Elastic deformation is temporary and fully recovers when 
the load is removed. This linear region is defined by Hooke’s Law, which states that stress is 
proportional to strain. Plastic deformation is permanent and is not recovered when the load is 
removed. 
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Figure 3. Stress-strain diagram for deformation of drug particles. (diagram adapted  
from www.brown.edu/.../EEB/EML/images/deformation.jpg ) 
 
The yield strength represents the stress required to generate permanent deformation and 
indicates the degree of easiness to deform the materials. The slope of the stress-strain curve in 
the elastic deformation region is the modulus of elasticity, which is known as Young's modulus. 
It represents the stiffness of the material-resistance to elastic strain. Beyond the yield point, the 
region represents irreversible plastic deformation. The increasing dislocation density makes 
plastic deformation more difficult. This phenomenon is the strain hardening. The strain at failure 
occurs after the particle fractures. It is the interaction point of the plastic recovery region in strain 
axis also known as ductility. The ductility is the percentage of elongation at failure and indicates 
that the general ability of the material to be plastically deformed. The toughness is used to 
describe the combination of strength and ductility. The area under the curve represents the 
fracture toughness; this is a proximal measure of the impact strength of the material. The fracture 
of a particle can be obtained when the mechanical force exceeds the elastic limit [12-19]. 
Particle size reduction to micrometric range influences greatly the dissolution rate and is 
described by the Noyes-Whitney equation. The ratio dm/dt is thereby defined as dissolution rate. 
From equation it is clear that increasing the surface area ( ) of a drug particle enhances its 
dissolution rate. 
 
 
 
 
 
S
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dm = amount of drug(Kg) 
dt = time interval (s) 
h = thickness of the diffusion film 
adjacent to the dissolution surface(m) 
S = surface (m2) D = diffusion coefficient(m2/s) 
Ct  = concentration of  
the dissolved drug (mol/L) 
Cs = saturation solubility of the drug molecule (mol/Kg H20) 
V = volume of dissolution medium (L) 
 
Vogt et al. [20] made a comparative study between different micronisation techniques 
(bead milling, jet milling) and their effect on the solubility of fenofibrate, a poorly soluble drug. 
Micronization of the fenofibrate was shown to enhance its dissolution (8.2% in 30 min) 
compared to the crude material (1.3% in 30 min). 
 
1.3.1.2. Nanonization 
 
Currently, most of the newly discovered drugs are so poorly water soluble that 
micronization is no longer sufficient to achieve the required bioavailability. The next step was to 
move from micronization to nanonization. By moving one dimension further to smaller particles, 
surface is further enlarged and the dissolution rate further enhanced. Saturation solubility is 
assumed as a constant depending on the compound, temperature and dissolution medium. 
However, bellow a critical size of 1 µm, saturation solubility (Cs) becomes also function of the 
particle size, increasing with the decrease of particle size. This effect on solubility is described by 
the Ostwald-Freundlich equation: 
  
)(
.
.
ts CC
hV
SD
d
d
t
m

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RTd
V
S
dS m.
exp
)(
0

  
S(d) = solubility (mol/Kg H20) 
d(m)= particle diameter) (m)  
T= temperature (K) 
R= gas constant (J/mol.Kg)  
Vm= molar volume  (m3/mol) 
 = surface free energy (surface tension) (mJ/m2) 
S0= solubility  of the bulk material ( ) (mol/Kg H20) 
 
Nevertheless, for the solubility S(d) to differ significantly from the solubility S0  of the 
bulk material, the exponential term needs to be much smaller than 1 as is the case for particles in 
the nanorange. Dissolution pressure increases with the increase of the curvature of the surface, 
i.e. by the decreasing particle size. The transfer of molecules from liquid phase to a gas phase 
(vapour pressure) is theoretically similar to the transfer of molecules from solid phase 
(nanocrystal) to liquid phase (dissolution pressure). At saturation solubility the equilibrium 
between molecules dissolving and molecules re-crystallizing is reached. This equilibrium can be 
altered in case the dissolution pressure increases. Taking into account the Kelvin equation allows 
a better understanding of the enhancement of saturation solubility by particle size reduction: 
 
 
 
P = vapor pressure(Pa) γ = surface tension (mJ/m2) 
P0 = equilibrium pressure(Pa) VL = molar volume (m3/mol) 
Cos θ = contact angle R = universal gas constant (J/mol.Kg) 
rk = radius of  droplet(m) T = absolute temperature (K) 
 
Applying Kelvin equation to compounds with different vapor pressures, demonstrated 
that the increase in vapor pressure with the decrease in droplet size is more significant in 
compounds with initial lower vapor pressure [21]. In analogy, the increase of dissolution pressure 
d
RTk
L
r
V
P
P
*
cos**
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0
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in solid particles is more pronounced in those with an initial lower dissolution pressure, i.e. the 
relative increase is higher in poorly soluble drugs. Such effect is exponential for particles with 
sizes bellow 100 nm [22]. 
Several techniques are used to obtain drug particles in the nanorange [27], and can be 
divided in either top down or bottom up processes as listed in Table 3.  The most common way 
is the size reduction of previously formed particle (top down process), using mechanical energy 
to induce impact, shear, attrition and cavitation. In a different approach bottom up 
techniques aim to produce small particles from solution by stimulating recrystallization into 
particles of a desired size, e.g. via spray drying or solvent displacement.  
 
Table 3. Processes and techniques for drug particle nanonization 
Nanonization methods Nanonization techniques 
Top down 
Pearl/Ball milling 
High pressure homogenization 
Bottom up 
Spray Freezing into liquid 
Liquid solvent exchange 
Supercritical fluids 
Controlled crystallization 
 
Milling can be carried out both in dry and wet state. This methodology is typically applied 
in the production of micro- or nano-suspensions for pulmonary administration [23]. For 
stabilization of the produced suspensions, stabilizing agents are used, including 
polyvinylpyrrolidone and poloxamers [24, 25]. When milling is performed in the presence of a 
surfactant a significant enhancement of drug dissolution rate and bioavailability can be achieved 
[26]. Liversidge et al. [28] investigated the effect on bioavailability of increasing the particle 
surface area by decreasing drug crystal particle size below 200 nm and stabilizing the particles to 
prevent agglomeration in the GI tract.  A randomized three-way crossover study was conducted 
to compare absolute oral bioavailability of danazol from three formulations: (a) an aqueous 
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dispersion of nanoparticulate danazol (mean particle size 169 nm); (b) danazol-hydroxypropyl-
beta-cyclodextrin (HPB) complex and (c) an aqueous suspension of conventional danazol 
particles. The bioavailability of nanoparticle suspension demonstrated that the nanoparticle 
dispersion had overcome the limited bioavailability observed with conventional suspensions of 
danazol. Alternatively, similar results were achieved by Muller et al. [30] by means of high-
pressure homogenization and by Pace et al. [29] using microfuidation. Milling is used by Elan for 
its NanoCrystal technology, which is currently licensed to Wyeth to produce Rapamune
 
and to 
Merck to produce Emend.  
Contrary to nanocrystalline drug formulation via milling, a bottom up approaches allow 
the production of drug particles directly in the required small particle size range. These 
methodologies are based on controlled crystallization phenomena. From dissolved state, 
assembly of drug molecules into agglomerates is induced under controlled conditions. The 
challenge in creating stable drug nanosuspensions is twofold, as besides preparing nanoparticles, 
they also have to be kept in the nanorange and thus prevent them from growing via Ostwald 
ripening or re-agglomeration. A common route to avoid particle growth is via the use of 
surfactants that coat the surface of the drug particles, preventing them from growing and provide 
steric or electrostatic repulsion to avoid particle aggregation. 
Furthermore, due to the Ostwald-Meyers rule, when engineering drug particles via a 
bottom up approach, the speed of the precipitation process is often crucial as super saturated 
conditions, smaller particles are obtained when nucleation occurs faster [31]. For this purpose, 
several techniques have been developed, including spray freezing into liquid, liquid solvent 
exchange and the use of supercritical fluids. 
Spray freezing into liquid (SFL) is a cryogenic particle engineering technique involving 
atomization of a drug solution into a cryogenic liquid (e.g. nitrogen) to produce small particles. 
The frozen particles are then lyophilized to obtain a free flowing powder. This technique has 
been extensively studied by Rogers et al. and Hu et al. to produce danazol nanoparticles. The 
obtained SFL powders significantly enhanced drug dissolution rate compared with micronized 
danazol [32, 33]. Similar results were obtained by the same research group using the EPAS 
(Evaporative Precipitation into Aqueous Solution) process. In this process, drug precipitation is 
induced by evaporation of an organic solvent from the feed solution near or above the boiling 
point upon contact with a heated aqueous solution [34]. Both techniques are presently 
commercialized by Dow Chemical Company. Based on the solubilization power of supercritical 
fluids (e.g. supercritical CO2) Li et al. developed the RESS (Rapid Expansion from a liquefied-gas 
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solution) technique to improve the dissolution of griseofulvin. After loading the supercritical 
fluid with drug, an extremely fast reversal from the supercritical phase to the gas phase occurs 
during expansion in a supersonic jet. This phase reversal induced super-saturation and 
subsequent particle precipitation. The obtained griseofulvin particles have sizes below 50 nm and 
exhibited an enhanced dissolution rate [35]. Young et al. achieved equivalent results upon 
preparing cyclosporine nanoparticles by RESS in a size range of 500-700 nm. In this case, Tween 
80 was used as surfactant to prevent flocculation and aggregation of the nanoparticles [36]. 
These approaches have been further explored by Pace et al. who combined the RESS 
technique with high-pressure homogenization to prepare a stable nanosuspension. In this 
process, a poorly water-soluble drug was first dissolved in a supercritical fluid, which was 
subsequently expanded into an aqueous solution containing surfactant. The thus formed 
suspension was further subjected to high-pressure homogenization, producing a stable 
nanosuspension [37]. Baxter has developed a similar process by combination of precipitation and 
shear forces, termed Nanoedge.  
 
1.3.2. Modifications of crystalline structure 
 
1.3.2.1. Polymorphs 
Although chemically identical, polymorphs exhibit different physicochemical properties 
such as solubility, melting point, density, texture and stability. Polymorphs can be classified as 
enantiotropes and monotropes, according to their thermodynamic properties. In enantiotropic 
systems, one polymorph form can change reversibly into another at a certain defined transition 
temperature below the melting point, while in monotropic systems such transition is irreversible. 
Drug molecules that fit into one of these categories undergo a 3-stage transition:  
Amorphous > Metastable polymorph > Stable polymorph. 
The metastable forms are associated with higher energy with increased surface area and 
consequently with increased solubility. The amorphous (i.e. no internal crystalline structure) form 
is more suitable to enhance drug solubility due to its higher energy state. Some drugs can already 
exist in an amorphous form and are commonly recognized as super cooled liquids. These have 
greater solubility than the crystalline forms because less energy is needed to transfer the molecule 
into solvent. 
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Similarly, an anhydrous form has better solubility than a hydrated form, since the latter 
one is already associated to water and have less energy for crystal breakup than anhydrates.  
Therefore in regard to bioavailability enhancement, it is better to use anhydrous forms or develop 
formulations of metastable and amorphous forms to enhance drug solubility. Ma et al. studied 
the two different polymorphic forms of 5-chloro-8-hydroxyquinolone, showing a much higher 
solubility and dissolution rate of polymorph form II [38]. Nevertheless, the possibility of a 
conversion of the high-energy form into a low-energy crystal with low solubility cannot be ruled 
out. During manufacture and storage, recrystallization and water incorporation may occur, 
endangering drug solubility performance and bioavailability. Greco et al. evaluated the 
crystallization of amorphous indomethacin during dissolution. The amorphous indomethacin was 
prepared either via quench cooling the melted solid or via cryogrinding. Both techniques 
apparently yielded amorphous drug. Nevertheless, only drug processed via quench cooling 
showed enhanced dissolution. Deeper investigation into the solid state characteristics of the drug 
formulations indicated the presence of small crystalline nuclei in the product obtained via 
cryogrinding that impaired the drug dissolution rate [39]. 
 
1.3.2.2. Co-crystals 
Co-crystals have emerged as a promising means to enhance drug solubility, dissolution 
and bioavailability [7, 8]. A co-crystal may be defined as a crystalline material that consists of two 
or more molecular (electrically neutral) species held together by non-covalent forces [40]. The 
formation of co-crystals requires the development of a supramolecular library of co-crystallizing 
agents derived from examining structure-properties relationships present in classes of known 
crystal structures [42]. Co-crystals are more stable, particularly as the co-crystallizing agents are 
solids at room temperature. Only three co-crystallizing agents are classified as generally 
recognized as safe (GRAS), including saccharin, nicotinamide and acetic acid, thereby limiting the 
pharmaceutical applications [41]. Co-crystallization between two active pharmaceutical 
ingredients has also been reported. At least 20 have been reported to date, including caffeine and 
glutaric acid polymorphic co-crystals [43]. Co-crystals can be prepared by different techniques 
including solvent evaporation, simultaneous grinding of different components, sublimation, melt 
crystallization, and slurry processing [44]. The formation of molecular complexes and co-crystals 
is becoming increasingly important as an alternative to salt formation, particularly for neutral 
compounds or those having weakly ionisable groups. There is nevertheless lack of precedence 
and emergent concerns about the safety and toxicity of co-crystal forming agents. 
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1.4. Solid solutions and solid dispersions 
A solid dispersion is a solid formulation consisting of at least two different components, 
generally a hydrophilic matrix (crystalline or amorphous) and an, often hydrophobic, drug. The 
drug compound in a solid dispersion does not necessary exist in a micronized state. Often a 
fraction of the drug is dispersed solubilized in the matrix or can be in amorphous state [45-48]. 
Upon exposure to aqueous medium, the carrier dissolves and releases the drug as fine colloidal 
particles. This will result in enhanced surface area and higher drug dissolution rate. During such 
process a portion of the drug goes immediately into solution (until saturation point is reached) 
while the remaining excess precipitates as fine colloidal particles. Based on the molecular 
arrangement of the drug within the matrix, different types of solid dispersions can be 
distinguished as listed in Table 4. 
 
Table 4 - Types of solid dispersions, adapted from Dhiendra K. et al [53]. 
Solid dispersion 
type 
Matrix * Drug** Remarks No. Phases 
I Eutectics C C The first type of solid dispersion 
prepared 
2 
II 
Amorphous 
precipitations 
in crystalline 
matrix 
C A Rarely encountered 1 
III 
Solid 
solutions 
    
 Continuous 
solid solutions 
C M Miscible at all composition, never 
prepared 
1 
 Discontinuous 
solid solutions 
C M 
Partially miscible, 2 phases even 
though drug is molecularly 
dispersed. 
2 
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Table 4 (CONT.) - Types of solid dispersions, adapted from Dhiendra K. et al [53](Cont.) 
 
Substitutional solid 
solutions 
C M 
Molecular diameter of drug (solute) 
differs less than 15% from the matrix 
(solvent) diameter. In that case the 
drug and matrix are interchangeable. 
Can be continuous or discontinuous. 
When discontinuous: 2 phases even 
though drug is molecularly 
dispersed. 
1 or 2 
 Interstitial solid 
solutions 
A M 
Drug (solute) molecular diameter 
less than 59% of matrix (solvent) 
diameter. 
Usually limited miscibility, 
discontinuous. Example: Drug in 
helical interstitial spaces of PEG. 
2 
IV Glass suspension A C 
Particle size of dispersed phase 
dependent on cooling/evaporation 
rate. Obtained after crystallization of 
drug in amorphous matrix 
2 
V Glass suspension A A 
Particle size of dispersed phase 
dependent on cooling/evaporation 
rate many solid dispersions are of 
this type 
2 
VI Glass solution A M 
Requires miscibility OR solid 
solubility, complex formation or 
upon fast cooling or evaporation 
during preparation, many (recent) 
examples especially with PVP 
1 
*A:matrix in the amorphous state, C: matrix in the crystalline state 
** A: drug dispersed as amorphous clusters in the matrix, C: drug dispersed as crystalline particles in the matrix, M: 
drug molecularly dispersed throughout the matrix 
 
 
1.4.1. Simple eutectic mixtures  
These solid dispersions are characterized by a molten mixture of a component A and B, 
in which, upon cooling both A and B crystallize simultaneously (Figure 4). Solid eutectic 
mixtures are commonly prepared by rapid cooling of a molten mixture, resulting in a mixture of 
very fine crystals of both components. When these mixtures incorporate a poorly soluble drug, 
its dissolution rate is strongly enhanced by increasing the crystal contact surface. Liu et al. 
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reported on the creation of a eutectic mixture of itraconazole and poloxamer 188, leading to at 
least a 33-fold increase in itraconazole solubility in water. [49]. 
 
Figure 4. Eutectic system phase diagram 
 
1.4.2. Solid solutions 
Solid solutions can be divided in several subdivisions. In continuous solid solutions, all 
components are miscible in all proportions. In theoretical terms it means that the bonding 
strength between components is stronger that the bonding strength between the molecules 
within each individual component. This is an ideal situation, but yet to be reported for 
pharmaceutical applications. 
In discontinuous solid solutions, the solubility of each component (α, β) in the other is 
limited. A typical diagram of a discontinuous solid solution is shown in Figure 5. The region 
labeled "α" is a solid solution, with β acting as the solute in a matrix of α. On the other end of the 
concentration range, the region labeled "β" is also a solid solution, with α acting as the solute in a 
matrix of β. The large solid region in between the α and β solid solutions, labeled "solid α and β", 
is not a solid solution. Instead, examination of the microstructure of a mixture in this range would 
reveal two phases — a solid solution α-in-β and a solid solution β-in-α would, forming two 
separate phases.   
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Figure 5. Diagram of a discontinuous solid solution 
In a classic solid solution within its crystalline structure the solute molecules can either 
substitute the matrix molecules if the size of the solute molecules differs less than 15% from the 
solvent molecule [50] forming a crystalline substitutional solid solution (Figure 6), or simply 
occupy the interstitial spaces between the matrix molecules in the crystal lattice and forming a 
interstitial solid solution. In an interstitial solid solution, the molecules of solute should have a 
diameter no greater than 0.59 of the matrix molecule [51] and a volume of less than 20% of the 
matrix. 
 
 
Figure 6. Substitutional solid solution (left) interstitial solid solution (right) 
 
In amorphous solid solutions, the solute molecules are molecularly solubilized in an 
amorphous matrix (Figure 7). Chiou and Riegelman [52] were the first to report an amorphous 
solid solution by using griesofulvin in citric acid, achieving an enhanced dissolution of the drug. 
Many other carriers have been used like urea, sugars (e.g. sucrose, dextrose, galactose) and more 
recently organic polymers such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and 
several cellulose derivates. These polymeric carriers are particularly interesting since they are likely 
to form amorphous solid solutions due to their inherent amorphous nature. The drug molecules 
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incorporated within these polymeric matrixes could additionally act as a plasticizer, reducing the 
glass transition temperature of the polymeric matrix. 
 
 
Figure 7. Amorphous solid solutions 
 
1.4.3. Glass solutions and suspensions 
A glass solution is a homogeneous glassy system where the solute is dissolved in a glassy 
matrix that acts as solvent. Such glassy or vitreous state is usually obtained by an abrupt cooling 
of a melt. This system is characterized by its transparency and brittleness below its glass transition 
temperature. Upon heating it progressively softens without a sharp melting point [51]. 
 
1.4.4. Methods for preparation of solid dispersions 
The fusion method, sometimes referred as the melt method (when the starting material 
is crystalline), was first proposed by Sekiguchi and Obi [53]. This process involves the 
preparation of a physical mixture of a drug a water-soluble carrier subjected to direct heat until a 
molten phase is obtained. The molten mixture is then rapidly solidified. The final mass is 
pulverized and sieved. Although frequently applied, the fusion method has some limitations: 
incompatibility between components results in a inhomogeneous solid dispersion [54], under 
slow cooling conditions, crystalline drug precipitates [55, 56], degradation of drug and or matrix 
during the heating to temperatures necessary to fuse matrix and drug and it can only be applied 
when matrix and drug are compatible and mixable at the melting temperature. 
Hot melt extrusion is essentially similar to the fusion method with the exception that 
intense mixing of the components is induced by an extrusion process. Compared with the 
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traditional fusion method, this technique allows obtaining a similar stability and dissolution, but 
offers the potential to shape the heated drug-matrix system into a desired form. Furthermore, it 
allows continuous production, making it suitable for large scale production. Den et al. [57] have 
investigated the solubility enhancement of fenofibrate by producing polymeric matrix pellets of 
low molecular weight (LMW) hydroxypropylcellulose polymers (Klucel EF, Klucel ELF and 
Klucel ELXF by Ashland Specialty Ingredients, USA) by hot melt extrusion (HME). Drug 
dissolution from the HME pellets was much faster rate than the pure drug. 
The solvent method involves a first step where matrix material and drug are solubilized 
in a common solvent. In a second step, the solvent is removed, forming a solid dispersion. The 
main advantage of this method is that thermal decomposition of the matrix material and/or drug 
can be prevented. Nevertheless some disadvantages are inherent to this method as super-
saturation of the drug in the matrix material can only be reached in systems with high viscosity 
[58]. Furthermore it might be difficult to find a common solvent for both matrix material and 
drug, as well as the elevated cost of preparation due to the use of organic solvent and posterior 
removal. 
Supercritical fluid techniques are mostly applied using carbon dioxide (CO2). The 
supercritical (Sc) CO2 is used either as a solvent for drug and matrix or as an non-solvent [59, 60]. 
When used as a solvent, both drug and matrix are solubilized in ScCO2 and the resulting solution 
is sprayed through a nozzle into an expansion chamber where upon adiabatic expansion the 
ScCO2 evaporates and particles are instantly formed. This technique is known as Rapid 
Expansion of Supercritical Solution (RESS), and considered a “solvent free” process since the 
CO2 is environmentally friendly.  
Other supercritical techniques are precipitation methods that take advantage of ScCO2 as 
an non-solvent. In a first stage the drug and matrix material are solubilized in an organic solvent, 
followed by precipitation induced by ScCO2. Some of those techniques are: Gas-Anti-Solvent 
(GAS) or Precipitation from Gas Saturated Solutions (PGSS), where a solution of matrix material 
and drug is brought in contact with ScCO2, and then after expansion and decrease of solvent 
strength, precipitation of particles occurs. In Precipitation with Compressed Anti-Solvent (PCA), 
a solution of drug and matrix is sprayed into a vessel containing a supercritical non-solvent, 
which rapidly penetrates into the droplets inducing particle precipitation [61]. 
In a somehow different approach but still considered a supercritical technique, Super 
Critical Fluid Impregnation is based on the solubilization of only the drug in the Sc fluid and 
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exposed to a solid matrix material that swells and absorbs the supercritical solution. By inducing a 
change in pressure and time of exposure, the diffusion process of the Sc fluid can be controlled 
[62]. The use of ScCO2 is advantageous as it is much easier to remove it from the polymeric 
materials in the end of the process, even the reminiscent amount will pose no danger to the 
patient.  
 
1.5. Complexation 
Complexation can be described as association between two or more molecules, forming a 
non-covalently bound entity with a well-defined stoichiometry. This association relies on 
relatively weak forces such as Van der Waals forces, hydrogen bonding and hydrophobic 
interactions. Several types of complexes exist depending on the complexing agent that is used. 
Some compounds are known to form stacking complexes (e.g. nicotinamid, salicylic acid, 
caffeine), due to large planar non-polar regions in the molecule. Stacked complexes can be 
homogeneous (association) or mixed (complexation). This causes some molecules to minimize 
the contact with water by aggregation of their hydrocarbon moieties. 
The exclusion of water from contact with non-polar molecules or molecular regions, can 
be obtained through inclusion into a host molecule. Complexation by inclusion takes place when 
non-polar molecules or molecular group (guest) are inserted in the cavity of another molecule 
(host). The cavity of the host should be sufficiently large to accommodate the guest and small 
enough to exclude water of contacting the guest. In pharmaceutical formulations, the most used 
host molecules are cyclodextrins. These compounds are obtained by degradation of starch by 
cyclodextrin-glycosyltransferase (CGT). Cyclodextrins are cyclic oligomers, crystalline and water-
soluble. There are three major groups of these cyclic oligosaccharides, α-, β- ,γ-cyclodextrins 
composed of six, seven and eight D-(+)-glucopyranose units. These compounds have a toroidal 
structure with primary and secondary hydroxyl groups oriented outwards, creating a hydrophilic 
exterior and hydrophobic internal cavity. Molecules or functional groups less hydrophilic can be 
included into the hydrophobic cyclodextrine cavity in the presence of water. The cavity size and 
possible chemical modification determines the affinity of cyclodextrins to various molecules. The 
solubility of a compound can be enhanced by inclusion within the cycodextrin cavity [63]. As an 
example it was shown that cyclodextrin complexation increases the solubility of paclitaxel with a 
950 fold [64] and similar were obtained for rofecoxib, celecoxib, clofibrate, melarsopol and 
cyclosporine A [65-69].  
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1.6. Solubilization by surfactants 
Surfactants are characterized by a tendency to absorb at surfaces and interfaces lowering 
the free energy of the phase boundary. The interface defines a boundary between to immiscible 
phases. When such boundary is covered with a surfactant compound, the energy necessary to 
expand the interface (surface tension) is greatly reduced. Surfactant molecules have distinct polar 
(or hydrophilic) and non-polar (or hydrophobic) regions, and are commonly designated as 
amphiphilic (Figure 8). Most surfactants are composed of a hydrocarbon chain (tale) connected 
to a polar group (head). The polar group can be anionic, cationic, zwitterionic or non-ionic [70]. 
Table 5 gives an overview of the different types of surfactants that are used for pharmaceutical 
applications. Besides the ability to decrease surface tension, surfactant molecules are also know 
by the capability to create association structures above their critical micelle concentration (Figure 
9). These two characteristics are of great importance in enhancing the solubility of poorly water-
soluble compounds. This occurs either by covering the interface of the poorly water-soluble drug 
particle will decrease the surface tension, allowing better wettability or by forming micelles that 
integrate the drug within their hydrophobic core. 
 
Figure 8. The primary classification of surfactants is made on the basis of the charge of the polar head group. 
 
Park et al. have extensively documented the effect of different types of surfactants 
(cetyltrimethylammonium bromide (CTAB) as cationic surfactant, sodium lauryl sulfate (SLS) as 
anionic surfactant, and polysorbate 80 as a non-ionic surfactant) on the dissolution behavior of 
poorly water-soluble acid drugs, including mefenamic acid, nimesulide and ibuprofen.  The 
dissolution of these acidic drugs was substantially enhanced in aqueous media containing 
CTAB. For acidic drugs, the ability of aqueous media containing a cationic surfactant to enhance 
dissolution of acidic drugs appeared greater than that of media containing other surfactant types 
[71].  
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Table 5 - Surfactants classification versus structure 
Surfactant 
type 
Hydrophilic 
group 
Hydrophobic group Comments 
Anionic 
Negatively 
charged group 
 
e.g. carboxyl, 
sulfonate, 
phosphate 
Long, straight alkyl groups 
Branched-chain alkyl groups 
Unsaturated alkenyl chains 
Alkylbenzenes 
Alkylnaphatalenes 
Fluoroalkyl groups 
Polydimethylsiloxanes 
Polyoxypropylene glycol 
derivatives 
Others (e.g. biosurfactants, 
derivates of natural and synthetic 
polymers) 
Generally non compatible with cationic 
surfactants, sensitive to water hardness.  
Cationic 
Positively 
charged group 
 
e.g. quaternary 
ammonium 
halides 
Generally non compatible with anionic 
surfactants. They adsorb strongly to 
surfaces and show high aquatic toxicity 
Zwitterionic 
Contains both 
positive and 
negative charge 
 
e.g. betaines, 
sulfobetaines 
Compatible with all other types of 
surfactants, not sensitive to hard water. 
Generally stable in acids and bases. 
Highly tolerated by the skin  
Nonionic 
No charge, highly 
polar group 
 
e.g. 
polyoxyetheylene, 
polyhydroxyl  
Compatible with all other types of 
surfactants, not sensitive to hard water. 
Contrary to ionic surfactants, their 
physicochemical properties are not 
affected by electrolytes. 
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Figure 9. Different types of surfactant associations 
1.7. Use of co-solvents 
A common approach to solubilize lipophilic drugs is the use of co-solvents [72]. A co-
solvent must have solvent capability towards a solute and be mixable with the solvent in which 
the solute is insoluble. [73]. The co-solvent decreases the surface tension between the aqueous 
solution and the hydrophobic solute [74]. Most co-solvents have hydrogen bond donors and/or 
receptors as well as a hydrocarbon chain. Through a mutual bonding to water and to lipophilic 
substances, a co-solvent is able to prevent precipitation of the insoluble compounds in water. In 
pharmaceutical formulation, currently the most used organic compounds with co-solvent activity 
are polyethylene glycol 400 (PEG 400), ethanol, propylene glycol and glycerine. An overview of 
solubilizing excipients in commercial oral and injectable formulations is given in Table 6. 
Badu et al. investigated the effect co-solvency with biocompatible solvents such as 
ethanol, propylene glycol, glycerin, and PEG 400, on the solubility enhancement of Cox-II 
inhibitors (meloxicam and rofecoxib). They found that less polar solvents were more potent 
enhancers of drug dissolution, with the solvent blend water-PEG 400 yielding the best results 
[75]. 
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Table 6 – Solubilizing excipients in commercial oral and injectable formulations 
Water Soluble Water Insoluble 
Dimethylacetamide (DMA) Oleic acid 
Ethanol Soy fatty acids 
Glycerin d-α-tocopherol (Vit. E) 
N-methyl-2-pyrrolidone (NMP) Corn oil mono-di-triglyecerides 
PEG 300 Medium chain triglycerides 
PEG 400 Long-chain triglycerides 
Poloxamer 407  Castor oil 
Propylene Glycol Corn oil 
Hydrogenated Soy Peanut oil 
 Caprylic/capric triglycerides 
  
 
 
 
1.8. Microemulsions and Self-emulsifying drug delivery systems (SEDDS) 
A microemulsion is a thermodynamically stable isotropical four-component system 
composed of an external phase, internal phase, surfactant and co-surfactant. The addition of the 
surfactant, soluble in the internal phase, results in the spontaneous formation of a microemulsion 
(internal dispersed phase is <0.1μm in droplet diameter) without the input of external energy as is 
the case in common emulsification processes. The formation of a mixed film composed of 
surfactant and co-surfactant at the interface between internal and external phase, contributes to 
the stability of the microemulsion [76]. Non-ionic surfactants (e.g. polysorbates and 
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polyoxyethylated oleic acids) with a high hydrophilic-lipophilic balance (HLB) are frequently used 
to ensure an immediate formation of the microemulsion mixing of both phases [77].  
Microemulsions have potential as drug delivery systems for poorly soluble drugs due to 
their capability to solubilize the lipophilic molecules in the internal phase. These formulations 
present several advantages over conventional emulsification, including thermodynamic stability, 
increased drug loading, decreased inter- and intra variability in drug pharmacokinetics and 
enhanced bioavailability [78, 79]. 
In the absence of an external phase, the mixture of the remaining components can form a 
so-called self-emulsifying drug delivery system (SEDDS). These systems are able, upon dilution 
in an aqueous phase, to spontaneously form fine O/W emulsion or microemulsions, improving 
water solubility of lipophilic drug. However, potential drawbacks of these systems include 
possible drug instabilities and high concentration of surfactants, leading to irritation in the gastro 
intestinal tract. Kadu et al. have studied the impact of self-emulsifying drug delivery systems in 
the oral bioavailability of atorvastatin calcium. The solubility of atorvastatin calcium was 
determined using various self-emulsifying components, including, Glyceryl 
Tricaprylate/Tricaprate (Captex®355 EP/NF, Abitec, USA), Ethyl oleate, Medium Chain Mono- 
and Diglycerides (Capmul®MCM, Abitec, USA), Propylene Glycol Monocaprylate (Capmul®PG-
8, Abitec, USA), Lauroyl macrogol-32 glycerides EP (Gelucire®44/14, Gattefosse, France), 
Polyoxyethylene (20) sorbitan monooleate (Tween 80, Tween 20 by ICI Americas Inc, USA) and 
Polyetheylene glycol 400. In vivo these formulations significantly reduced serum lipid levels 
compared to atorvastatin calcium [80]. 
 
 
 
 
 
 
 
 
  General Introduction – CHAPTER 1   
- 27 - 
1.9. Research work considerations 
This overview of both the solubility phenomena and the different formulation approaches used 
by formulation scientists towards the enhancement of drug solubility, allowed to define this 
research work.  Two distinct approaches were used: particle size reduction and the use of surface 
active substances, in order to enhance the solubility of three poorly soluble model drugs 
(carbamazepine, itraconazole and febantel) non using organic solvents during the process. 
These compounds qualify as BCS Class II drugs, demonstrating low aqueous solubility and 
variable bioavailability. 
In this work carbamazepine solubility is enhanced with the use of PEG-32 glyceryl laureate 
(Gelucire®44/14, Gattefossé, France). Perissuti et al, have described similar results for both 
Gelucire®44/14 and Gelucire®50/13 when used in the preparation of solid dispersion of 
carbamazepine with enhanced dissolution rate [81]. Furthermore, the use of Gelucire®44/14 and 
its capability to enhance carbamazepine dissolution rate has been further explored by Sethia et al, 
using solid dispersions of carbamazepine formulated by supercritical fluid processing (SCP) and 
conventional solvent evaporation in polyethylene glycol (PEG) 8000 with either Gelucire 44/14 
or vitamin E TPGS NF (d-alpha-tocopheryl PEG 1000 succinate), which contributed to an 
enhanced drug solubility [82]. 
Gelucire®44/14 was also used for the production of nano- and micro suspensions of itraconazole 
and febantel. Sun et al investigated the effect of particle size on the in vitro dissolution and oral 
absorption of itraconazol. The nanosuspensions were prepared by high pressure homogenization 
and stabilized by Lutrol F127 and sodium lauryl sulfate. These studies revealed faster drug 
dissolution rate with significant increase in both maximal plasma concentration of drug and area 
under the drug concentration-time curve [83]. The presence of Gelucire®44/14 and its effect on 
itraconazole solubility behavior has been described by Robini and collaborators, they enhanced 
dissolution of itraconazole by developing solid dispersions using water-soluble carriers 
polyglycolized fatty acid esters (Gelucire®44/14 and Gelucire®50/13), Vitamin E TPGS (d-alpha 
tocopheryl polyethylene glycol-1000 succinate), polyethylene glycol 6000 (PEG 6000) and urea. 
These solid dispersions of itraconazole and water-soluble carriers exhibited the highest 
dissolution rate for the observed period of 2 hours, which was about two-fold as compared to 
that of control itraconazole formulation [84].  
In parallel, similar tests were conducted with febantel as model drug. Up until today no data on 
solubility enhancement of this probenzimidazole are available. This drug is widely use in animal 
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large scale medication and its primary way of administration is through drinking water. Its low 
solubility together with everyday application in veterinary practice made it the ideal candidate for 
the development of a new solubilization technique based on the preparation of a highly loaded 
drug coacervate phase by using polyethoxylated castor oil (Cremophor®EL, BASF). 
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2.1. INTRODUCTION 
 
Rapid and complete drug absorption is one of the key objectives in designing 
conventional oral solid dosage forms. Most orally administered drugs are absorbed via passive 
diffusion through the small intestine, where the extent of absorption is largely influenced by drug 
solubility in the gastrointestinal fluids and drug permeability through the gastrointestinal 
membrane [1]. Many of the currently developed new chemical entities are poorly water-soluble. 
To overcome this challenge, polymeric non-ionic surfactants are attractive excipients to enhance 
drug solubility. Amongst these, Gelucires® are polyethylene glycol (PEG) glycerides composed of 
mono-, di- and triglycerides and mono- and diesters of PEG [2]. They are inert semi-solid waxy 
amphiphilic excipients with surface-active properties that spontaneously form a fine dispersion or 
emulsion upon contact with water [3]. The different varieties of Gelucires® are characterized by a 
range of melting points and hydrophilic-lipophilic balance (HLB) values, with high HLB 
Gelucires® allowing faster drug release due to their increased hydrophilicity [4, 5]. Mehuys and 
co-workers demonstrated that hot-melt extruded core-shell rods comprising a core of Gelucire® 
44/14 could release the poorly water-soluble drug hydrochlorothiazide in a controlled fashion [6]. 
Capsules filled with a Gelucire®44/14 matrix were reported by Massik to enhance the dissolution 
rate of phenytoin [7]. Spray-drying from organic medium was demonstrated by Chauhan to yield 
solid dispersions of etoricoxib with enhanced dissolution kinetics [8]. 
However, the use of Gelucire®44/14 in the above mentioned examples has several 
limitations regarding the development of immediate release formulations of poorly water-soluble 
drugs. The long erosion time of monolithic Gelucire®44/14 structures is often the rate-limiting 
step in these formulations while the need for organic solvents involves the burden of toxic 
residual solvents.  
In this paper we aim to develop a formulation strategy based on Gelucire® for immediate 
release of poorly water-soluble drugs without using organic solvents. As a model drug 
carbamazepine is used while melt granulation and spray-drying from aqueous medium are used to 
produce granules and respectively powder that is then further compacted into tablets. 
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2.2. MATERIALS AND METHODS 
2.1.1. Carbamazepine  
Carbamazepine (Figure 1 shows scanning electron microscopy images of the crude drug 
and Figure 2 shows its molecular structure) is a poorly water-soluble (water solubility of 17 
mg/L) Biopharmaceutical Classification System (BCS) Class II drug. It is a weak base with a pKa 
of 13.9. Carbamazepine is used as an anticonvulsant and mood-stabilizing drug for treatment of 
epilepsy and bipolar disorder. It is also used off-label for a variety of indications including 
attention-deficit hyperactivity disorder (ADHD), schizophrenia, phantom limb syndrome, 
paroxysmal extreme pain disorder and post-traumatic stress disorder. The mechanism of action 
of carbamazepine occurs through interaction with the neuronal sodium channels as well as the 
gamma-aminobutyric acid (GABA) receptors. The carbamazepine used in the present work was 
purchased from Fagron. 
 
 
        Figure 1. Scanning electron microscopy (SEM) images  at different magnification of crude carbamazepine. 
 
Figure 2. Molecular structure of carbamazepine 
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2.2.2. Gelucire ®44/14 
 Gelucire®44/14 is the trade name under which PEG-32 glyceryl laureate is sold by 
Gattefossé. It is an inert semi-solid waxy amphiphilic material with a melting point of 44°C and 
an HLB of 14. Gelucire®44/14 is GRAS (generally regarded as safe) and obtained by 
polyglycolysis of hydrogenated palm kernel oil with poly(ethylene glycol) 1500. Due to its 
composition of hydrophilic and hydrophobic parts, it has self-emulsifying properties, 
spontaneously forming a fine emulsion upon contact with water. 
 
2.2.3. Other excipients 
Citric acid and sodium bicarbonate were purchased from Fagron. Hard gelatin capsules 
size 000 were purchased from ACA Pharma. Microcrystalline cellulose (Avicel® PH 102) and 
cross-linked sodium carboxymethyl cellulose (Ac-di-sol®) were purchased from FMC 
Biopolymer. Pre-gelatinzied starch (C*Gel-instant 12410) was obtained from Cerestar. 
Polyplasdone® XL was purchased from ISP, Explotab® from Penwest.  
 
2.2.4. Formulation of carbamazepine in gelatin capsules  
 Carbamazepine was dispersed in molten Gelucire®44/14 at 60°C under stirring during 10 
min. Table 1 list the different ratios used for this formulation. The molten mass was immediately 
injected into hard gelatin capsules and allowed to cool to room temperature for 24h. 
 
Table 1: Carbamazepine/Gelucire
®
44/14 ratios used to formulate hard gelatin capsules 
Drug/excipient 
ratio 
Carbamazepine 
(mg) 
Gelucire®44/14 
(mg) 
Total   
(mg) 
1 to 1 200 200 400 
1 to 2 200 400 600 
1 to 3 200 600 800 
1 to 4 200 800 1000 
1 to 5 200 1000 1200 
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2.2.5. Formulation of carbamazepine via melt granulation 
 A mortar was heated in a water bath set at 60 °C. Carbamazepine was first mixed with 
microcrystalline cellulose or pre-gelatinized starch and then granulated in the heated mortar with 
molten Gelucire®44/14. Finally the granules were passed through a 1.25 mm sieve. To enhance 
the dissolution rate of the carbamazepine a series of granules were fabricated with the addition of 
excipients that should enhance the disintegration of the granules. Table 2 gives an overview of 
the respective amounts of drug and excipient to produce the formulations. 
 
Table 2: Carbamazepine/excipient ratios used for melt granulation 
Granules Carbamazepine (g) Excipients Amount (g) Total (g) 
Formulation 1 (G1) 20 
Gelucire®44/14   
pre-gelatinized Starch  
20 
20 
60 
 
Formulation 2 (G2) 
 
20 
Gelucire® 44/14  
microcrystalline cellulose  
20 
20 
60 
G2+ Ep* 20 Explotab® 3 63 
G2+ Ac* 
20 Ac-di-sol® 3 63 
G2+ Py* 20 Polyplasdone® XL 3 63 
G2+ EF mix 20 mixture citric acid with 
sodium bicarbonate 
3 
 
63 
 
*Excipients added to the dry powder mixture before granulation 
 
2.2.6. Formulation of carbamazepine via spray-drying 
 An aqueous suspension was prepared by first dissolving 100 g of Gelucire®44/14 in 1 L 
demineralized water at 50 °C. Subsequently, carbamazepine and additional excipients were added 
and the suspension was homogenized using a Silverson L4R high shear mixer at 6000 rpm. The 
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ratios of the different components are listed in Table 3. The mixture was spray-dried in a Mobile 
Minor (GEA Niro) spray-dryer equipped with a two-fluid nozzle (1 mm diameter) and a Watson 
Marlow 520U peristaltic pump set at 20 mL/min. The spray-dryer was operated in a co-current 
flow with a constant inlet temperature of 140 °C and an outlet temperature of 55 °C.  After 
spray-drying a free-flowing powder was collected.   
 
Table 3: Carbamazepine/excipient ratios used for spray drying 
Spray dried powder  Carbamazepine (g) Excipients Amount (g) Total (g) 
Formulation 1 (SD1) 100 
Gelucire®44/14   
Pre-gelatinized Starch  
Mannitol 
Silicon dioxide 
Demineralized water 
100 
45 
45 
20 
1000 
600 
 
Formulation 2 (SD2) 
 
100 
Gelucire®44/14  
Microcrystalline cellulose  
Mannitol 
Silicon dioxide 
Demineralized water 
100 
45 
45 
20 
1000 
600 
SD2+ Ep* 100 Explotab® 30 630 
SD2+ Ac* 
100 Ac-di-sol® 30 630 
SD2+ Py* 100 Polyplasdone®XL 30 630 
*Excipients that were added to the spray dried powder 
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2.2.7. Production of carbamazepine tablets 
 The spray-dried powder and the granulates were compacted (10 kN) using an eccentric 
Korsch EKO tablet press equipped with a 13 mm circular flat edge punch. The tablets were 
tested for their disintegration time on a Pharma Test PTZ disintegrator in 900 mL of a 0.1 M 
HCl solution at 37 °C. 
2.2.8. X-ray diffracion 
X-ray diffractograms of the spray-dried powder and granules were recorded on a D5000 
Cu K diffractor (λ=0.154 nm) (Siemens, Karlsruhe, Germany) with a current of 40 mA in the 
angular range of 10° < 2θ < 60° using a step scan mode (step width 0.02°, counting time 1 
s/step). 
2.2.9. Optical microscopy 
Optical microscopy images were recorded on Leica DM2500P microscope equipped with 
a 40x objective and a DFC360FX CCD camera. Hot stage microscopy was performed on the 
same microscope, but then equipped with a THMS600 heating stage. 
2.2.10. Scanning electron microscopy (SEM) 
 SEM images were recorded on gold-sputtered samples using a Quanta 200 FEG FEI 
scanning electron microscope, operating at an acceleration voltage of 5 kV. 
2.2.11. In vitro drug release 
 Carbamazepine release from the respective formulations was evaluated (N=6) under sink 
conditions in a VanKel VK7010 dissolution tester combined with a VK8000 automatic sampling 
station. Per dissolution vessel, formulations containing 200 mg of carbamazepine were used. The 
dissolution medium was 900 ml 0.1 M HCl at 37 °C. 5 mL samples were withdrawn from the 
dissolutions vessels at 5, 10, 15, 30, 30, 45 and 60 min (for the granules, spray-dried powder and 
tablets) and at 5, 10, 15, 20, 30, 45, 60, 75, 120 and 180 (for the capsules).  
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2.2.12. Quantification of carbamazepine release via HPLC 
 Carbamazepine concentrations in filtered (to remove non-dissolved particulates) 
dissolution samples were determined via a high performance liquid chromatography (HPLC) 
method according to the European Pharmacopoeia. Prior to analysis, samples were diluted 1:4 
with methanol. The HPLC set-up consisted of a solvent pump (L-7100 pump, Merck Hitachi) set 
at a constant flow rate of 1.5 mL per minute, an automatic injection system (L-7200, Hitachi,), a 
variable wavelength UV-detector (L-7400, Merck Hitachi,) set at 230 nm, a reverse phase column 
(LiChrospher®100 CN -10 µm, Merck) and an automatic integration system (D-7000, Hitachi). 
The mobile phase consisted of 3% tetrahydrofuran, 12 % methanol, 85 % water, 0,02 % 
anhydrous formic acid and 0.05 % triethylamine.  
 
2.3. RESULTS AND DISCUSSION 
In this work several formulation strategies based on Gelucire®44/14 were evaluated to 
enhance the dissolution kinetics of the poorly water-soluble drug carbamazepine. To set a 
reference formulation, we first dispersed carbamazepine in molten Gelucire®44/14, followed by 
filling this dispersion into hard gelatin capsules. To assess whether melting of Gelucire®44/14 to 
60 °C followed by mixing with carbamazepine leads to either a solid dispersion or a solid 
solution, X-ray diffraction was performed. As shown in the diffractograms depicted in Figure 
3A, no substantial influence of the heating and mixing process on the crystallinity of the 
carbamazepine is observed. Furthermore, optical microscopy images recorded on a heating-stage 
set up (Figure 3B) showed that at 60 °C, the carbamazepine is dispersed as solid crystalline 
material in a molten Gelucire®44/14 phase. This eliminates the possibility that the crystalline 
peaks observed in the X-ray diffractogram of the heated carbamazepine: Gelucire®44/14 mixture 
result from carbamazepine that was first dissolved in the molten Gelucire®44/14 phase and then 
recrystallized upon cooling to room temperature.  
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Figure  3. (A) X-ray diffractograms of carbamazepine, Gelucire
®
44/14, a physical mixture of both components and 
a mixture that was prepared under heating at 60 °C. (B) Hot stage microscopy images recorded from a 50:50 
carbamazepine/Gelucire
®
44/14 mixture (B1) at room temperature, (B2) at 60 °C and (B3) after cooling back to 
room temperature. 
 
The influence of different carbamazepine/ Gelucire®44/14 ratios on the drug dissolution 
kinetics were evaluated in vitro and compared to crude carbamazepine. 0.1 M HCl was used as 
dissolution medium, set at a constant temperature of 37°C. As shown in Figure 4, crude 
carbamazepine resulted in only 10 % dissolution under the given conditions. By contrast, the 
hard gelatin capsules filled with the solid carbamazepine/Gelucire®44/14 dispersion yield a nearly 
complete drug release within 2 hours. Furthermore, no influence of the 
carbamazepine/Gelucire®44/14 ratio was observed, indicating that the rate-determining step in 
drug release from these formulations was the dissolution of the Gelucire®44/14 itself, which 
occurs through surface erosion. Since nearly-complete drug release was observed for a 1:1 drug: 
excipient ratio, this ratio was used for further experiments.  
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Figure 4. Cumulative in vitro release of carbamazepine formulated in hard gelatin capsules filled with a solid 
carbamazepine/Gelucire
®
44/14 dispersion in different drug: excipient ratios. Crude carbamazepine (CBZ) was used 
as reference. 
 
 In a next series of experiments we aimed to enhance the drug dissolution rate of 
carbamazepine, envisioning an immediate release formulation. Therefore, we sought for 
production methods that enhance the surface to volume ratio of the obtained formulations. This 
is especially the case for particulate formulations, which are expected to exhibit accelerated drug 
release relative to a monolithic structure of the same material. First, we attempted to perform 
melt granulation using Gelucire®44/14 both as liquid and as binder. As carrier excipient for 
granulation, microcrystalline cellulose (referred to as G1) and pre-gelatinized starch (referred to 
as G2) were evaluated. This would allow us to investigate whether the addition of a hydrophilic 
excipient could further enhance the dissolution kinetics of the obtained formulations. In both 
cases, the total drug load was 30 %. Figure 5 shows SEM images of the obtained granules. 
Secondly, we evaluated spray-drying to produce immediate release solid dosage forms. Therefore, 
Gelucire®44/14 was first dispersed in demineralized water followed by the addition of 
carbamazepine, and either microcrystalline cellulose (referred to as SD1) or pre-gelatinized starch 
(referred to as SD2). Furthermore, to increase the yield of the spray-drying process, silicon 
dioxide as glidant and mannitol as bulking agent were added prior to spray-drying. Figure 5 
shows SEM images of the obtained microparticles. 
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Figure 5. SEM images at different magnifications of the respective granules and spray dried microparticles. G1, G2, 
SD1 and SD2 are defined in Tables 2 and 3. 
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 Figure 6 shows the effect on drug release of these different formulation strategies, with a 
nearly complete release being achieved within 30 min. Clearly, both the granulation and the 
spray-drying process strongly increase the rate of drug dissolution compared to the hard gelatin 
capsules filled with a solid dispersion of carbamazepine in Gelucire®44/14. This demonstrates 
that formulating carbamazepine and Gelucire®44/14 in a particulate rather than a monolithic 
form is beneficial to obtain an immediate release formulation. The use of either microcrystalline 
cellulose or pre-gelatinized starch was not found to influence drug release profile, neither in the 
granulated nor in the spray-dried formulation. Between the latter two groups a slightly faster 
release was observed for the spray-dried formulation. This is likely due to the smaller particle size 
of the spray-dried powder relative to the granules as evident from the SEM images in Figure 5, 
showing large (> 100 µm) chunky granules and spray dried microparticles which all have a size 
below 20 µm.  
 
 
Figure 6. Cumulative in vitro release of carbamazepine formulated with Gelucire
®
44/14 via granulation or spray-
drying. ‘1’ refers to formulations containing pre-gelatinized starch as co-excipient, while ‘2’ refers to microcrystalline 
cellulose as co-excipient. Crude carbamazepine (CBZ) and hard gelatin capsules filled with a solid 
carbamazepine/Gelucire 44/14 solution in a 1:1 drug: excipient ratios were used as reference. 
 
 In a next step, we aimed to transform the granulated and spray-dried formulations into a 
form that is suitable for oral intake. Therefore, these particulate forms were compacted into 
tablets under a compaction force of 10 kN using 13 mm flat end punches. Figure 7 shows SEM 
images of the tablets and their interior, obtained by splitting the tablets in half. Figure 8 shows 
the cumulative drug release profiles of the respective tablet formulations. These profiles indicate 
a significant decrease of the drug release rate upon compaction into tablets, being quasi equal to 
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the hard gelatin capsules filed with a solid dispersion of carbamazepine/Gelucire®44/14. The 
major reason for this is likely the long time it takes for the tablets to disintegrate, while this step is 
crucial to allow further wetting of the bulk of the tablets prior to drug dissolution. Table 4 lists 
the disintegration time of the respective tablet formulations. Gelucire®44/14 has a melting point 
of 44°C and behaves at room temperature as a waxy plastic solid. Therefore, under compression, 
Gelucire will redistribute and bridge multiple granules or spray-dried particles, forming a 
monolithic structure as shown by SEM imaging of the tablet surface and tablet interior (Figure 
7). Apparently, the presence of the water-soluble pre-gelatinized starch in both the tablets 
produced from granules and spray-dried powder, does not play a role in promoting tablet 
disintegration. 
 
 
Table 4: average disintegration time of CBZ tablets 
Tablet 
Average(±SD) disintegration time (min) 
in 0.1N HCl at 37°C (±0.5) 
TG1 27±0.69 
TG2 
25±0.82 
TSD1 22±0.69 
TSD2 
21±0.9 
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Figure  7. SEM images at different magnification of the respective tablet formulations. To image the interior of the 
tablets, the tablets were manually split in half and imaged perpendicular on the fraction plane. TG1, TG2, TSD1 and 
TSD2 are defined in Tables 4. 
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Figure  7. SEM images at different magnification of the respective tablet formulations. To image the interior of the 
tablets, the tablets were manually split in half and imaged perpendicular on the fraction plane. TG1, TG2, TSD1 and 
TSD2 are defined in Tables 4. (Cont.) 
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Figure 8. Cumulative in vitro release of carbamazepine formulated with Gelucire
®
44/14 via either granulation or 
spray-drying, followed by compaction into tablets. ‘G’ refers to tablets produced from granules while ‘SD’ refers to 
tablets produced from spray-dried powder. Crude carbamazepine (CBZ) and hard gelatin capsules filled with a solid 
carbamazepine/Gelucire
®
 44/14 solution in different drug: excipient ratios were used as reference. 
 
 To cope with these issues and thus to obtain an immediate release tablet formulation, we 
evaluated several types of super-disintegrants [9 -11] to be added during the formulation steps. 
For this purpose, 10 % of either Explotab®, Ac-di-sol® or Polyplasdone®XL were added to the 
spray-dried powder (after spray-drying, but prior to compaction) (Table 3) or to the powder 
mixture prior to melt granulation (Table 2). For these experiments only microcrystalline cellulose 
was used as co-excipient while pre-gelatinized starch was discarded. The reason for this is that the 
previous experiments showed no beneficial effect of pre-gelatinized starch on the dissolution 
kinetics. From the obtained granules and spray-dried powder, tablets were produced using 
identical settings regarding compaction force and punch size as described earlier in this work. 
These tablets were evaluated for their degradation time and drug release and as shown on Table 
5 and Figure 9, the addition of super-disintegrants only leads to a minor improvement in the 
drug dissolution kinetics. In the presence of super-disintegrants slightly more drug is released 
during the first 30 min, for all three types of super-disintegrants and for both the tablets 
produced from granules as well as those produced from spray-dried powder. Although differing 
in chemical structure, these super-disintegrants exert their effect in a similar way, i.e. by fast water 
uptake leading to swelling. This swelling is intended to disrupt the binding forces that hold the 
tablet. However, the limited effect of super-disintegrants on the disintegration time (Table 5) of 
the tablets produced in the present work is likely due to the presence of Gelucire®44/14.  
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Table 5: average disintegration time of CBZ tablets containing 
 Explotab
®
; Ac-di-sol
®
 and Polyplasdone
® XL. 
Tablet 
Average(±SD) disintegration time (min) 
in 0.1N HCl at 37°C (±0.5) 
TG2 EP 16±1.21 
TG2 AC 16±0.94 
TG2 PY 17±0.75 
TSD2 EP 15±0.76 
TSD2 AC 16±0.96 
TSD2 PY 16±0.69 
TG2 EF mix 2±0.29 
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Figure 9. dissolution profiles of CBZ tablets obtained by compression of spray dried powder mixture and granules 
containing Explotab
®
 (EP); Ac-di-sol
®
 (AC) and Polyplasdone
®
 XL (PY). 
 
 In a final series of experiments we replace the super-disintegrants by an effervescent 
mixture composed of citric acid and sodium bicarbonate in a 1:1 ratio. An effervescent powder 
mixture is generally composed of an acid and a bicarbonate, which readily react upon contact 
with water, releasing carbon dioxide. This effervescent mixture was added to the 
carbamazepine/microcrystalline cellulose mixture prior to melt granulation with Gelucire®44/14, 
in the same ratios as used for the earlier super-disintegrants. From the obtained granules, tablets 
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were produced using the same compaction force and punch size as described above. As shown in 
Figure 10, addition of the effervescent mixture to the formulation dramatically increased the 
drug dissolution rate, reaching more than 90 % of drug release in less than 10 min. Measuring the 
disintegration time of these tablets also elucidated that complete tablet decomposition took place 
in less than 2 min. These data indicate that, unlike swelling exerted by common super-
disintegrants, the mechanical force exerted by the formation of CO2 gas bubbles is capable of 
disrupting the bonds within the tablet.  
 
Figure 10. Dissolution profiles of CBZ tablets obtained by compression of spray dried powder mixture and granules 
containing Explotab
®
 (EP); Ac-di-sol
®
 (AC) and Polyplasdone
®
 XL (PY) and the effervescent mixture (EF mix). 
 
2.4. CONCLUSIONS 
 In this chapter we have demonstrated that the dissolution rate of a poorly water-soluble 
model drug, carbamazepine, can be greatly enhanced through formulation with Gelucire®44/14. 
However, to achieve immediate drug release it was found that a particular rather than a 
monolithic structure was found to be crucial. However, when granules or spray-dried powder 
were further processed into tablets this was found to reduce the drug dissolution rate to the level 
of a monolith. Addition of super-disintegrants to the tablet formulation did not result in similar 
dissolution properties as those of the granules of spray-dried powder prior to tabletting. 
However, replacing the super-disintegrants by an effervescent mixture of citric acid and sodium 
bicarbonate was found to overcome the tablet integrity and lead to immediate drug release. 
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3.1. INTRODUCTION 
One of the major causes of new drug molecules failing to reach the market is poor 
bioavailability. Indeed, many of the newly discovered drug candidates suffer from low to 
extremely low water solubility and hence are prone to limited bioavailability. To cope with these 
issues, drug formulation scientists are developing formulation strategies that enhance the 
dissolution, and thus bioavailability of these poorly water-soluble drugs. These strategies include, 
formation of inclusion complexes with cyclodextrins, salt formation, transformation of crystalline 
to amorphous, particle size reduction, etc...  
Amongst these techniques, particle size reduction is highly promising. Micronization of 
drug crystals to the lower micron range increases the surface area, thereby enhancing the drug 
dissolution rate in the gastrointestinal tract. For the simplified case of spherical particles, size 
reduction with a factor 10 (e.g. from 100 µm to 10 µm), a 100-fold increase in surface area is 
obtained. However, for extremely hydrophobic drug molecules, micronization is not sufficient to 
achieve high enough bioavailability [1, 2]. Therefore, reducing particle size to the nanorange 
(increasing the surface area of the drug crystals with multiple orders of magnitude) has been 
investigated through several approaches. Basically, these can be divided into two main groups: 
top-down and bottom-up techniques. In a top-down approach, nanoparticles are produced by 
exposing drug particles to mechanical energy, either through impact, shear or ultrasound induced 
cavitation. Drawbacks of these approaches are the limited control over the final particle size and 
morphology and the risk for potential contamination originating from the grinding media or 
ultrasonication set-up. Bottom-up approaches involve controlled recrystallization of dissolved 
(typically in organic solvents) drug molecules into nanoparticles via e.g. spray-drying or solvent-
displacement. These approaches allow, by optimizing solvent and stabilizer (e.g. surfactants) a 
better control over particle size and morphology. However, a major drawback is the use of 
organic solvents that holds the risk of residual traces of organic solvents that can hardly be 
removed. 
When producing crystalline drug nanosuspensions, several considerations should be taken 
into account. First of all, colloidal stability of the nanosuspension is an important issue as 
reaggregation of hydrophobic nanocrystals readily takes place when these are not stabilized by 
means of surface active molecules. Reaggregation decreases the total drug surface area, thereby 
decreasing drug dissolution kinetics and should thus be avoided. Secondly, drug concentration 
plays an important role as for practical reasons excessive dilution of the nanosuspensions should 
be limited. Related to the latter is the further processing of the nanosuspensions into a solid 
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form, while still allowing a nanosuspension to reform in aqueous physiological medium (e.g. in 
the gastrointestinal tract). 
This study aims to evaluate different solvent-free approaches to produce 
nanosuspensions of poorly water-soluble drugs in order to enhance their dissolution behavior. As 
model drugs, itraconazole (Figures 1A and 2A); and febantel (Figures 1B and 2B) were chosen 
due to their extremely low water solubility.  
In order to stabilize the drug nanosuspensions, we will co-formulate the drug 
nanocrystals with non-ionic surfactants. Whereas a first top-down approach is based on simple 
grinding of crystalline drug suspended in liquid surfactant, we focus in the other approaches on 
using cavitation induced by ultrasonic waves to control the drug particle size. Cavitation is the 
formation of gas bubbles in a liquid phase in regions where the pressure of the liquid falls below 
its vapor pressure. Due to acoustic waves, the gas bubbles oscillate in size and upon collapse of 
the bubbles, a shock wave is produced. These shock waves have sufficient power to erode 
crystalline material into smaller particles in a top-down process as well as avoiding nanoparticle 
aggregation in a bottom-up process [3]. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
Febantel (melting point of 166 °C and water solubility of 1.9 µg/ml) was obtained from 
Fagron (Belgium) and itraconazole (melting point of 130 °C and water solubility of 1 ng/ml) was 
obtained from Johnson & Johnson (Belgium). Figure 1 shows optical microscopy images of both 
drugs in crude form and their molecular structure is shown in Figure 2. Febantel is a broad-
spectrum probenzimidazole that is widely used against gastrointestinal nematodes and lung 
worms in live stock [3-8]. It is a prodrug that is metabolized in vivo to fenbendazole and further to 
oxfendazole, 4-hydroxyfembendazole, 4-hydroxyfendazole, and an inactive metabolite 
febendazolesulfone [9-14]. Itraconazole is a triazole antifungal drug, used in the treatment of 
fungal infections. 
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Figure 1. Optical microscopy images of (A) itraconazole and (B) febantel. 
 
Gelucire®44/14 (i.e. PEG-32 glyceryllaurate) was obtained from Gattefossé (France). 
Gelucire®44/14 is an amphiphilic semisolid with a melting point of 44°C and an HLB of 14. 
Gelucire®44/14 is GRAS (generally recognized as safe) and is obtained by polyglycolysis of 
hydrogenated palm kernel oil with polyethylene glycol 1500. Due to its unique composition, 
comprising mono- and diesters of PEG, mono-, di- and triglycerides, it spontaneously forms a 
microemulsion upon contact with water [15]. These properties allow Gelucire®44/14 to be used 
in the solubilization enhancement of poorly soluble drugs and increase of their solubility rate [16, 
17]. 
 
Figure 2. Molecular structure of (A) itraconazole and (B) febantel. 
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3.2.2. Preparation of the nanosuspensions 
The composition of the nanosuspensions containing itraconazole (water solubility 1 
ng/mL) and febantel (water solubility 1.9 µg/mL) is displayed in Table 1. 
 
Table1. Composition of the crude febantel and itraconazole suspensions 
Formulation 
components 
(wt %) (g) 
Gelucire®44/14  10,1 20 
water 
75,7 150 
febantel 14,2 28,14 
Gelucire®44/14  11,5 20 
water 
85,9 150 
itraconazole 2,6 4,54 
 
3.2.2.1. Wet milling 
Drug, Gelucire®44/14 and water were added to a 500 mL zirconium dioxide grinding 
bowl loaded with 25 zirconium dioxide grinding beads of 20 mm in diameter. The bowl was 
closed with a zirconium dioxide lid, placed in a ball mill type Pulverisette 6 (Fritsch, Idar-
Oberstein, Germany) and allowed to rotate at 350 rpm for a fixed time interval. 
 
3.2.2.2. Indirect sonication  
First, Gelucire®44/14 was dispersed in water followed by the addition of the crude 
crystalline drug powder. The experimental set-up is schematically shown in Figure 3. The 
ultrasonic mini flow cell was obtained from Hielscher Ultrasonics (Teldow, Germany) and 
attached to a titanium sonotrode type BS2d22 (HielscherUltrasonics) and an ultrasound generator 
type UIP1000 (Hielscher Ultrasonics), operating at 20 kHz (± 1kHz) and an intensity of 20 
W/cm².  The ultrasonic mini flow cell consists of a glass tube connected to a closed tubing circuit 
in which the aqueous drug/Gelucire®44/14 suspension is injected through a syringe connected to 
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a valve. The total volume of the system is approximately 30 ml. The tubing is inserted in a 
peristaltic pump to allow circulation of the suspension. The residence time of the suspension in 
the flow cell can be controlled via the peristaltic pump. Additionally, the ultrasonic mini flow cell 
contains a water jacket (room temperature), surrounding the glass tube (4 mm in diameter), 
connected with a pressurized water reservoir. This water jacket allows propagation of the 
generated ultrasonic waves, transmitting them to the suspension within the glass tube. 
Furthermore, the water jacket allows controlling the temperature of the glass tube limiting the 
heating caused by the ultrasonication. 
 
 
 
Figure 3. Schematic representation of the experimental set-up for indirect sonication of drug suspensions.  (a) 
ultrasonic processor, (b) pressurized water tank, (c) security pressure valve, (d) compressed air input, (e) water pump, 
(f) syringe, (g) close cycle valve, (h) peristaltic pump, (i) sonotrode, (j) glass tube, (k) ultrasonic mini flow cell, (1:2) 
pressurized water input/output, (3;4) suspension input/output. 
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3.2.2.3. Ultrasonic melt crystallization 
Figure 4 shows a schematic representation of the experimental set-up to produce drug 
nanosuspensions via ultrasonic melt crystallization. A photograph of the set-up is shown in 
Figure 5. Itraconazole and febantel were first dissolved in Gelucire®44/14 at respectively 150°C 
and 140°C, which is above their respective melting point. Subsequently, the liquid phase was 
atomized through a 2 fluid nozzle into a dual wall stainless steel flow cell containing 150 mL 
water. The water was thermostatized at 10°C to allow prompt cooling of the atomized liquid. The 
temperature was monitored by an in line temperature probe. During the atomization process, 
cavitation was induced to the system by means of an ultrasonic probe (HielscherUltrasonics, 
Teldow, Germany) composed of a titanium sonotrode type BS2d22 (HielscherUltrasonics), a 
booster type B2-1.4 (HielscherUltrasonics) and an ultrasound generator type UIP1000 
(HielscherUltrasonics) operating at 20 kHz ± 1 kHz, and an intensity of 100W/cm2. After 5 
minutes of sonication, milky suspensions of both drugs were obtained 
 
 
 
Figure 4. Schematic representation of the ultrasonic melt crystallization set-up. (a) sonotrode, (b) ultrasonic 
processor, (c) digital thermometer, (d) cooling system, (e) titanium tip, (f) booster, (g) two fluid nozzle, (h) heating 
cord, (i) temperature probe, (j) dual wall flow cell, (d1, d2) inputs for the cooling circuit. 
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Figure 5. Photograph of the experimental ultrasonic melt crystallization set-up. 
 
3.2.3. Particle size distribution 
The particle size distribution of the drug crystals in the nanosuspensions was determined 
by laser diffraction using a Malvern Mastersizer S (Malvern Instruments, Spring Lane South, UK) 
equipped with a small volume dispersion unit and a 300 RF lens. Water was used as dispersion 
medium for all measurements. 
 
3.2.4. Optical microscopy 
Optical microscopy images were recorded under bright field and polarized light using a 
Leica 2500P microscope equipped with 10x and 63x oil-immersion objectives, a DFC360FX 
CCD camera and a Linkham THMS600 heating stage. To allow proper visualization, drug crystals 
and nanosuspensions were squeezed between two glass cover slides. 
3.2.5. Experimental design 
An experimental design was set up to evaluate the influence of the drug to Gelucire® 
44/14 ratio and ultrasonication time on the particle size of the nanosuspensions produced via 
ultrasonic melt crystallization. As model drug only febantel was evaluated and a central composite 
experimental design was chosen. The febantel to Gelucire®44/14 ratio (ranging from 0.1 to 0.5) 
and the ultrasonication time (ranging from 0 to 60 minutes) were used as variables and the 
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D(v,0.9) particle size was the response factor. In total 13 experiments were performed in 
randomized order as listed in Table 2. The experimental runs and the output results were 
processed via Design Expert-software (version 6.0.10, Stat-Ease, USA). 
Validation of the prediction model was performed by comparing the predicted particle 
size to the observed value for a random point of the design (sonication time: 20 min, febantel to 
Gelucire ratio: 0.3). Table 3 shows that the 95% confidence interval of the observed value was 
within the 95% prediction interval. 
 
Table 2: Experimental design variables and response factor, for a total of 13 experiments 
Variables Response factor 
Experiment 
Number 
 
Ratio 
Drug/Gelucire®44/14 
(w/w) 
Sonication Time 
[min] 
Particle size  
[μm] 
1 
0.5 30.0 4.58 
2 0.3 60.0 4.97 
3 0.4 8.8 9.45 
4 0.16 8.8 0.28 
5 0.3 30.0 4.74 
6 0.3 30.0 4.36 
7 0.3 30.0 3.18 
8 0.44 51.2 15.17 
9 0.3 0.0 2.38 
10 0.1 30.0 0.26 
11 0.3 30.0 9.39 
12 0.3 30.0 7.11 
13 0.16 51.2 0.32 
 
Dv(0,9) = -1.170 + 10.144 * ratio + 0.011 * time 
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Table 3: Validation of the prediction model. 
 
3.2.6. In vitro drug dissolution  
Drug release from the produced nanosuspensions was evaluated in a VK7010 dissolution 
bath (VanKel Industries, NJ, USA) equipped with a VK8000 automatic sampling station (VanKel 
Industries, NJ, USA). All dissolution tests were run in triplicate. Note that since this study 
focused on the development of formulations that enhanced the dissolution rate of extremely 
poorly water-soluble drugs, sink conditions were not met. As dissolution medium, 900 ml 0.1 M 
HCl in demineralized water was used at a temperature of 37°C. At 5, 10, 15, 20, 30, 45 and 60 
minutes, 5 ml samples were withdrawn from the dissolution vessels without medium 
replacement, filtered through a 200 nm filter to remove particulate matter and analyzed by 
spectrophotometry for their drug content.  
 
3.2.7. Analytical method validation 
 
The febantel concentration was measured at 280 nm and itraconazole concentration was 
measured at 260 nm using a double beam spectrophotometer (Shimadzu UV-1650 PC, Shimadzu 
CO., Kyoto, Japan). 
The UV-spectroscopy method was validated based on the guidelines stated by the 
International Conference on Harmonization (ICH) for validation of analytical procedures (1994). 
The following characteristics were considered: specificity, linearity, accuracy, precision, detection 
and quantification limit. The parameter of recovery was not evaluated since no extraction step is 
involved. 
 
Response 
factor 
Predicted value 
[μm] 
95% Prediction 
interval [μm] 
Observed 
value [μm] 
95% Confidence 
interval [μm] 
D(v,0.9) 4.42 [1.07; 10.05] 5.62 [3.010; 5.97] 
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Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of other compounds. 
Such can be assessed by comparing the UV spectrum of the different components of the 
formulation on Figure 6 and verifying that no interference is observe at the considered 
wavelengths of 260nm (itraconazole) and 280nm (febantel). It is clear that both methods are 
selective to determine the amount of each drug in the dissolution medium. 
 
Figure 6. Specificity of the UV method. 
Linearity 
The linearity of the analytical procedure is its ability – within a given range – to produce results 
which are directly proportional to the concentration of drug in the dissolution medium sample. 
For the validation of the present UV-spectroscopy methodologies several calibration curves were 
performed for both drugs. The linearity of the calibration curves was evaluated by the 
determination of the coefficient R2. The mean determination of the calibration curves (n=6) was 
0.999 for itraconazole and 0.999 for febantel, indicating a linear relationship between absorption 
and concentration. Equation of the mean calibration curve was:  
Y=35.77±0.35x + 0.0009±0.00003 for febantel (concentration range 0.003 to 0.031mg/mL) 
Y=40.02±0.8x + 0.0061±0.0007 for itraconazole (concentration range of 0.001 to 0.021mg/mL) 
 
With x= drug concentration (mg/mL) and y=absorption. 
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Accuracy 
The accuracy of analytical procedure expresses the closeness of agreement between the true value 
and the determined value; it’s expressed as the percentage agreement between the mean 
determined and the true concentration. 
The accuracy was investigated in three concentration levels. Each concentration was determined 
six times. The mean accuracies (±SD) are listed in Table 4 and Table 5. 
Table 4: Accuracy (±SD) of UV-method for febantel (n=6) 
Concentration 
(mg/mL) 
Accuracy % 
Within-day Between-day 
0.003 
106.9 ± 3.4 109.9 ± 6.6 
0.015 101.2 ± 2.3 98.9 ± 2.9 
0.031 99.7 ± 1.8 101.3 ± 1.2 
 
 
Table 5: Accuracy (±SD) of UV-method for itraconazole (n=6) 
Concentration 
(mg/mL) 
Accuracy % 
Within-day Between-day 
0.001 
97.7 ± 8.6 101.6 ± 10.5 
0.011 91.0 ± 2.5 91.8 ± 2.9 
0.021 101.1 ± 0.8 100.7 ± 1.0 
 
All mean values are within ±15% of the actual concentration. 
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Precision 
Precision expresses the closeness of agreement between repeated determinations. It may be 
considered at three levels: repeatability (intra-intra assay precision), intermediate precision (within 
laboratory precision) and reproducibility (between laboratory precision). Precision is expressed as 
the coefficient of variation (%) of a series of measurements of the calibration standards. Since the 
measurements were performed in the same laboratory, by the same person using the same 
equipment only the repeatability (within-day and between day) of the measurements was 
evaluated. The precision was assessed by assaying three standards in six replicate in one day for 
within-day precision and once daily for six days for between-day precision (Table 6 and 7), the 
acceptance criteria are coefficients of variation less than 15%. 
 
Table 6: Precision (expressed as coefficient of variation) of the UV-method for febantel (n=6) 
Concentration 
(mg/mL) 
Within-day Between-day 
x  SD Precision (%CV) x  SD Precision (%CV) 
0.003 0.14 0.0015 1.1 0.15 0.005 3.5 
0.015 0.55 0.0045 0.8 0.54 0.004 0.75 
0.031 1.12 0.0047 0.4 1.11 0.004 0.39 
 
 
Table 7: Precision (expressed as coefficient of variation) of the UV-method for itraconazole (n=6) 
Concentration 
(mg/mL) 
Within-day Between-day 
x  SD Precision (%CV) x  SD Precision (%CV) 
0.001 0.043 0.0053 12.3 0.15 0.0044 9.7 
0.011 0.412 0.0223 5.4 0.54 0.0217 5.2 
0.021 0.861 0.059 6.8 1.11 0.0148 1.7 
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Detection and quantification limit 
The detection limit of an analytical procedure is the lowest amount of analyte in a sample which 
can be detected but not necessarily quantified as an exact value. The quantification limit is the 
lowest amount of analyte in a sample that can be adequately determined with suitable precision 
and accuracy. Both values are estimated from the mean calibration curve (ICH, 1995). 
 
 
   
     
 
 
 
DL= detection limit 
σ= standard deviation of the Y-intercept of the mean calibration curve 
S= slope of the mean calibration curve 
 
  
   
    
 
 
 
QL= quantification limit 
σ= standard deviation of the Y-intercept of the mean calibration curve 
S= slope of the mean calibration curve 
 
 
The detection and quantification limits of febantel and itraconazole in the dissolution samples 
were DL=8.3x10-5 mg/mL ,QL=2.5x10-4 mg/mL and DL=5x10-4 mg/mL, QL=1.5x10-3 mg/mL 
respectively. 
 
 
 
3.2.7. X-ray diffraction (XRD) 
X-ray diffractograms were recorded on a PANalytical X'Pert PRO X-ray diffractometer 
(Siemens). XRD patterns were obtained with Cu KR radiation (45 kV x 40 mA; λ = 1.5406 A) at 
a scanning speed of 25° (2θ)/min and step size of 0.03° (2θ). Measurements were done in the 
reflection mode in the 2θ range of 5-40°.  
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3.3. RESULTS AND DISCUSSION 
3.3.1. Preparation of nanosuspensions 
 As mentioned above, itraconazole and febantel are used in this study as model poorly 
water-soluble drugs. Both drugs are highly crystalline with a mean diameter D (v, 0.5) of 
respectively 26 µm (itraconazole) and 232 µm (febantel) as measured by laser diffraction. Figure 
1 shows optical microscopy images of both drugs in crude, unprocessed form. A first step in our 
formulation strategy was suspending the crystalline drug in Gelucire®44/14 and water. A first 
series of preliminary screening experiments served to determine the Gelucire®44/14 to drug ratio 
that allows processing via all 3 formulation processes. The respective formulation parameters are 
shown in Table 1.  
 
 
Figure 7.(A) Size distribution, measured by laser diffraction, at different time points during wet milling of 
respectively itraconazole and febantel suspensions in Gelucire
®
44/14 . The dotted arrows indicate the ‘micro’ drug 
crystal population to diminish as function of process time in favour of the ‘nano’ population. (B) Corresponding 
evolution of the D values as a function of process time.  
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3.3.1.1. Wet milling 
 Wet milling is frequently used to produce drug nanosuspensions, and was used in this 
work as reference process. The crude aqueous drug/Gelucire®44/14 suspensions were added to a 
bowl containing zirconium dioxide as grinding medium, and were subsequently placed during 1 h 
in a ball mill at 350 rpm. Figure 7A, shows the evolution of the particle size distribution and the 
mean particle diameter, measured by laser diffraction, during the wet milling process. These data 
demonstrate that for both febantel and itraconazole the initial particle population decreases as a 
function of process time, while a new sub-micron population emerges. Although efficient to 
produce drug nanosuspensions, the wet milling process bears several disadvantages. First of all, 
relatively long milling times are required. Secondly, there is a potential risk of contaminating the 
drug formulation with particulate matter resulting from erosion of the milling components. A 
third limitation is the possibility of only batch wise production. 
. 
 
Figure 8. (A) Size distribution, measured by laser diffraction, at different time points during indirect sonication of 
respectively itraconazole and febantel suspensions in Gelucire
®
44/14 . The dotted arrows indicate the ‘micro’ drug 
crystal population to diminish as function of process time in favor of the ‘nano’ population. (B) Corresponding 
evolution of the D values as a function of process time.  
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3.3.1.2. Indirect sonication 
 To cope with the above mentioned issues related to wet milling, we aimed to design a 
process that allows to generate energy input without exposing the drug molecules to potential 
sources of contamination. Therefore, we constructed in-house an ‘indirect sonication’ set-up. 
Table 8. Overview of the D values, measured by laser diffraction, of itraconazole and febantel drug suspension after 
different process times during respectively wet milling and indirect sonication. 
process time [min] 
 
 
D(v,0.1) 
[µm] 
D(v,0.5) 
[µm] 
D(v,0.9) 
[µm] 
 
  
 
itraconazole 
milling sonication 
 
 milling sonication milling sonication milling sonication 
15 30 
 
 0.35 0.4 2.29 4.51 7.08 20.21 
30 60 
 
 0.3 0.33 1.4 2.08 4.54 6.57 
45 90 
 
 0.3 0.3 1.26 1.3 4.13 4.29 
60 120 
 
 0.29 0.28 1.07 0.96 3.66 3.36 
   
 
febantel 
milling sonication 
 
 milling sonication milling sonication milling sonication 
15 30 
 
 0.29 0.89 1.53 4.1 4.11 8.95 
30 60 
 
 0.27 0.29 0.7 1.16 2.75 4.78 
45 90 
 
    0.28 0.27 0.91 0.92 3.36 3.72 
60 120 
 
    0.26 0.34 0.58 0.65 2.2 3.06 
 
Figure 8 displays the evolution of the particle size, measured by laser diffraction. Similar 
to the wet milling process, the particle size decreased as function of the process time. Again, 
febantel showed a more profound down-sizing of the particle diameter than itraconazole. We 
also observed that the efficiency of down-sizing can be optimized by extending the residence 
time of the liquid in the flow cell by controlling the pump rate. Lower pump rates lead to longer 
residence times in the flow cell and allowed to shorten the total process time. The indirect 
sonication process clearly has the advantage that the drug is not in contact with the physical 
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energy source, thus avoiding potential contamination. Furthermore, this process is expected to be 
more suitable for up-scaling, either by enlarging the flow-through cell or by putting several cells 
in series. Additionally, this process should allow working in a continuous way with constant in-
and-out flow of fresh drug suspension, while the earlier described wet milling process is a batch 
process. Nevertheless, the indirect sonication process still suffers from relatively long, i.e. 2h, 
process times that are required to significantly reduce the drug crystal size. To summarize, Table 
8 gives an overview of the volume distributions (D values) of the drugs particles during 
processing via wet milling and indirect sonication. 
 
3.3.1.3. Ultrasonic melt crystallization 
 To cope with the issue of prolonged process times associated with both wet milling and 
indirect sonication, we developed a novel bottom up approach that we termed ‘ultrasonic melt 
crystallization’.  In this process, drug nanosuspensions are generated by dissolving the drug in a 
molten phase of Gelucire®44/14 at respectively 140 °C (itraconazole) and 150°C (febantel). The 
process of drug dissolution in a molten Gelucire®44/14 phase was deeper analyzed by hot stage 
microscopy and presented in Figure 9. At 60 °C a liquid Gelucire®44/14 phase exists in which 
the crystalline drug is suspended. As soon as the melting point of the respective drugs is reached, 
they dissolve in the liquid Gelucire®44/14 phase. Upon cooling to room temperature, the drug 
(or a part of the drug) recrystallizes from the solution into very fine particles in case of febantel 
and larger precipitates in case of itraconazole, as shown in Figure 9. 
 During the ultrasonication process, the molten drug/Gelucire®44/14 mixture was 
atomized through a two-fluid nozzle into a flow cell containing water thermostatized at 10°C. 
Furthermore, during atomization of the molten drug/Gelucire®44/14 phase, cavitation is induced 
by immersion of an ultrasonic probe. After 5 min of sonication, milky suspensions of both drugs 
were obtained. Figure 4 gives a schematic representation of the experimental set-up and Figure 5 
shows a photograph.  
As shown in Figure 10 on the size distribution graphs, the ultrasonic melt crystallization 
approach allowed to dramatically reduce the drug particle size. Importantly, whereas wet milling 
and indirect sonication yielded a bi-modal size distribution, the ultrasonic melt crystallization 
approach resulted in a mono-modal drug nanosuspension. In case of itraconazole, the D(v,0.5) 
reduced from 20.6 µm (i.e. the crude crystalline material before melting in Gelucire®44/14 ) to 
0.51 µm, while in case of febantel the D(v,0.5) was reduced from 153.7 µm to 0.38 µm (Table 9).   
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Figure 9. Optical microscopy images recorded using a hot stage microscopy set-up, demonstrating the dissolution of 
febantel, respectively itraconazole in a liquid Gelucire
®
44/14 phase as soon as the melting point of the drug is 
reached. The panels a, b and c show images at 10 s time intervals. Upon cooling to room temperature, (partial) re-
crystallization occurs.  
  
 This is due to a series of events that occur during the process. First, the drug is dissolved 
in a molten Gelucire®44/14 phase through heating. Secondly, the atomization of liquid 
Gelucire®44/14 droplets into cold water under intense cavitation induces flash precipitation of 
the drug into small crystals. Cavitation plays a crucial role in this process, preventing 
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agglomeration of the newly formed crystals [18]. Indeed, when we conducted control 
experiments in absence of ultrasonication, the atomized liquid immediately gelified upon contact 
with the cold water, followed by nucleation of drug crystals and further on the formation of large 
crystalline precipitates. By contrast, performing the process under ultrasonication readily allowed 
the Gelucire®44/14 to emulsify upon contact with the water and to control the nucleation of 
drug crystals, stabilizing these within the nano-range. 
 
 
Figure 10. Size distribution, measured by laser diffraction, of the drug (itraconazole, respectively febantel) crystals in 
crude state (red curves) and after ultrasonic melt crystallization. 
 
Table 9. Overview of the D values, measured by laser diffraction, of itraconazole and febantel before and after 
ultrasonic melt crystallization. 
  
D(v,0.1) 
[µm] 
D(v,0.5) 
[µm] 
D(v,0.9) 
[µm] 
  
itraconazole 
crude 
 
9.1 26 71 
processed 
 
0.26 0.51 1.25 
  
Febantel 
crude
 
36 232 480 
processed 
 
0.26 0.38 0.56 
 
 To investigate the influence of sonication time and drug to Gelucire®44/14 ratio on the 
final particle size, an experimental design was constructed. For this purpose we took only 
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febantel as model drug and in total 13 series of experiments were performed as listed in Table 2. 
As visualized by the 3D surface plot in Figure 11, particle size reduction is more efficient at 
lower drug to Gelucire®44/11 ratios and at shorter sonication times. Reducing the drug to 
Gelucire®44/14 ratio evidently decreases the total amount of drug in the system thus requiring 
more time for nucleating drug crystals and drug molecules to reach each other through diffusion. 
Thereby, the increased amount of Gelucire®44/14 allows a better stabilization of the newly 
created drug crystal surface, preventing agglomeration of the drug crystals. The influence of 
sonication time on the resulting particle size is less pronounced. However, the relative short 
required sonication times compared to the indirect sonication process described above is 
certainly beneficial to limit potential contamination of the drug formulation with metal 
nanoparticles that are eroded from the metal ultrasonication tips over prolonged sonication 
periods. 
 
 
Figure 11. 3D surface plot demonstrating the influence of drug to Gelucire
®
44/14 ratio and sonication time on the 
particle size of febantel crystals produced via the ultrasonic melt crystallization process. 
 
3.3.2. In vitro drug dissolution of drug nanosuspensions 
 Finally, the itraconazole and febantel nanosuspensions were evaluated for their in vitro 
dissolution behavior. The cumulative release curves of the respective formulations and their 
controls are shown in Figure 12. Table 10 summarizes the maximum concentration of drug that 
was dissolved. Crude drug, as well as a physical mixture of drug and Gelucire®44/14 give very 
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low drug concentrations, for both febantel and itraconazole. By contrast, the cumulative drug 
release curves depicted in Figure 12A, show a pronounced enhancement in total drug release for 
febantel processed via all three formulation strategies. Febantel formulated via ultrasonic melt 
crystallization achieves the highest total drug dissolved followed by indirect sonication and wet 
milling in a third place. Importantly, maximum drug concentration is reached within 10 min after 
addition of the nanosuspensions to the dissolution medium. In case of itraconazole only 
ultrasonic melt crystallization (Figure 12B) was able to increase drug dissolution.  
 For febantel, on the first sight, merely reducing the particle size (Figure 10) is effective to 
enhance drug dissolution; however, this is not the case for itraconazole. Probably this is due to 
the extremely poor water solubility of itraconazole (i.e. 1 ng/ml), which is even several orders of 
magnitude lower than febantel that has a water solubility of 1.9 µg/ml. To further investigate why 
the ultrasonic melt crystallization is the only process that effectively enhances the dissolution of 
itraconazole we assessed the crystallographic state of the formulated drug by X-ray diffraction 
(XRD). Figure 13 shows the corresponding X-ray diffractograms for all febantel and 
itraconazole formulations and the respective controls. These diffractograms show, relative to a 
physical mixture of drug/Gelucire®44/14 in the same ratio as used for the respective 
formulations, a significant reduction in crystallinity only for the formulations (of both drugs) that 
were processed via ultrasonic melt crystallization. The other formulations strategies had no 
detectable influence on the crystalline state of the drug. Hence, it is likely that ultrasonic melt 
crystallization produces a certain fraction of amorphous drug that contributes to the observed 
enhanced drug dissolution.  
 
Table 10. Maximum drug solubility in 0.1 M HCl at 37°C obtained via the respective formulation strategies. 
Formulation Febantel (µg/mL) Itraconazol (µg/mL) 
crude drug 0.55 ± 0.05 1.5 ± 0.1 
physical mixture  
drug/Gelucire 44/14  
0.8 ± 0.05 2.8 ± 0. 2 
wet milling 8.8 ± 0.5 6.3 ± 0. 1 
indirect sonication 17.45 ± 1.5 3.0 ± 0. 2 
ultrasonic melt crystallization 21.3 ± 0.5 4.5 ± 0. 5 
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Figure 12. Cumulative in vitro in 0.1 M HCl at 37 °C release of (A) febantel and (B) itraconazole 
formulated via either wet milling, indirect sonication or melt crystallization. As controls, crude 
unprocessed drug and a physical mixture of drug and Gelucire®44/14 were taken. 
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Figure 13.  X-Ray diffractograms of the respective (A) febantel and (B) itraconazole formulations. 
 
The relevance of both itraconazole nanoparticles and amorphous state in enhancing drug 
solubility has been acknowledged by several research works. Van Eerdenbrugh  et al, evaluated 
the effect of different stabilizing systems (povidone-K25, poloxamer-188 and TPGS-1000) and 
concentrations on the media milling efficiency of itraconazole and their impact on the dissolution 
behavior of the freeze-dried nanosuspensions, observing a faster dissolution rate compared with 
pure drug [19]. 
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  Miller et al, produced by means of rapid flocculation amorphous itraconazole 
nanodispersions stabilized with hydroxypropylmethylcellulose (HPMC) or the pH-sensitive 
Eudragit® L100-55 with enhanced drug solubility and higher in vitro supersaturation (AUC) of the 
flocculated nanoparticle dispersions, relative to the AUC for a commercially available 
itraconazole formulation, Sporanox [20]. Similar results have been described by Choi and 
Collaborators, when developing amorphous solid emulsions of itraconazole by the combined use 
of membrane emulsification and spray drying solidification technique using  Transcutol HP and 
Span 20 as a stabilizer, and dextran as solid carrier. The solid emulsion containing amorphous 
itraconazole displayed a significant increase in the dissolution rate than that of pure itraconazole. 
Furthermore, the solid emulsion after oral administration gave about eight-fold higher AUC and 
about ten-fold higher C(max) in rats than pure itraconazole powder [21]. The use of drug 
amorphous state as solubility enhancement alternative has been further explored by DiNunzio et 
al in the production of itraconazole solid dispersions by a novel high energy fusion technique 
KinetiSol® Dispersing (KSD).  The obtained amorphous solid dispersions of itraconazole (ITZ) 
and hypromellose exhibited near complete drug supersaturation in dissolution and enhanced 
AUC upon oral bioavailability compared to crystalline itraconazole [22]. 
 
3.4. CONCLUSIONS 
 In this chapter, we have developed several solvent-free strategies to produce micro- and 
nanosuspensions of poorly water-soluble drugs. To enhance the water-solubility of these drugs, 
Gelucire®44/14, a self-emulsifying biocompatible excipient, was used. Wet milling and indirect 
sonication yielded drug suspensions with a bimodal size distribution, comprising submicron 
particles and particles in the lower micron range. Ultrasonic melt crystallization was able to yield a 
unimodal drug suspension with submicron drug particles. All three strategies to reduce the size of 
the drug crystals in the presence of Gelucire®44/14 strongly enhanced the dissolution rate and 
total amount of dissolved drug for febantel. In case of itraconazole, only ultrasonic melt 
crystallization was able to enhance the dissolution rate and total amount of dissolved drug. This 
was attributed to the lower water solubility of itraconazole, relative to febantel, and the fact that 
ultrasonic melt crystallization produces a fraction of amorphous drug that is stabilized by 
Gelucire®44/14. 
Although enhancing dissolution rate and solubility of itraconazole using melt precipitation this 
technique remains inferior to other techniques described in literature for amorphisation. 
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4.1. INTRODUCTION 
For the treatment of veterinary diseases of livestock, mass medication is often preferred 
over individual treatment of animals. For this purpose, drug administration via the drinking water 
is highly convenient. This strategy is not only cost- and labor-saving but also targets sub-clinically 
affected animals as well as animals in the incubation stage of the disease. Compared to feed 
medication, drinking water medication allows a faster initiation of the treatment and faster dose-
adjustment while the risk of disease carry-over between consecutive food containers is less [1,2]. 
However, the administration of medication via drinking water offers specific challenges for 
poorly water-soluble drugs. Whereas drug resorption of solid oral dosage forms of poorly water-
soluble drugs is enhanced by surface-active properties of bile salts, this is not the case when 
poorly water-soluble drugs are added to a drinking water reservoir. By consequence, drug 
precipitation is likely to occur, leading to inhomogeneous drug distribution and thus large 
variation in medication levels in the drinking nipples [3, 4].  
The above-mentioned issues are of particular relevance for antiparasitic and antibacterial 
drugs such as chloramphenicol, febendazol and febantel, which are extremely poor water-soluble. 
To enhance the dissolution of poorly water-soluble drugs, several strategies have been developed, 
including size reduction of the drug crystals to the nano-scale, the formation of solid solutions, 
cocrystals, complexation with cyclodextrins, formation of microemulsions etc… However, for 
veterinary purposes as drinking water medication, the above-mentioned formulation strategies 
suffer from elevated cost and also retain the drug molecules in a crystalline state. Aggregation of 
drug crystals is likely to occur win the drinking water reservoir and will not only limit drug 
dissolution kinetics, but will also lead to inhomogeneous drug distribution in the drinking water 
reservoir and thus large variation in drug concentration that is administered to livestock animals. 
Therefore, we aimed to develop a formulation strategy for poorly water-soluble veterinary 
drugs that allows prompt drug dissolution in drinking water reservoirs. An attractive strategy to 
enhance drug solubility is the use of biocompatible non-ionic surfactants. Commonly, these are 
used to enhance the drug dissolution kinetics by lowering the surface tension and to increase the 
saturation concentration. In the present work, we modified this approach by directly dissolving 
the drug in a liquid surfactant phase. For this purpose, we used febantel, an extremely poor 
water-soluble broad-spectrum probenzimidazole that is widely used against gastrointestinal 
nematodes and lungworms in livestock. It is a prodrug that is metabolized in vivo to fenbendazole 
and further to oxfendazole, 4-hydroxyfembendazole, 4-hydroxyfendazole, and an inactive 
metabolite febendazolesulfone [5-7]. Following solubilisation in a liquid surfactant phase, we 
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sought to transform the formulation into a solid dosage form allowing easy handling, 
transportation and use.  
 
 
Figure 1. Molecular structure of (A) febantel and (B) maltodextrin. 
 
4.2. MATERIALS AND METHODS 
4.2.1. Materials 
Febantel was purchased from Fagron. Maltodextrin with a dextrose equivalent of 8 
(Pharmadry C*01983) was obtained from Cargill. Tapioca dextrin (k-4484) was purchased from 
National Starch. Cremophor®EL was obtained from BASF. FITC-dextran (Mw~500 kDa) was 
obtained from Invitrogen. Rhodamine B Octadecyl ester was obtained from Fluka. The 
deuterated solvents D2O and MeOH-d4 were obtained from Acros. 
 
4.2.2. Production of the liquid coacervate 
150 g of Cremophor®EL was heated to 130°C, which is just above the melting point 
(MP) of febantel (i.e. MP of 129°C). Subsequently, 60 g febantel was added and allowed to 
dissolve under stirring. Dissolution took about 2.5 min and the solution was left to stir for 
another 2 min to assure homogenization. The liquid was then immediately poured in 1L of a 30 
% (w/w) aqueous maltodextrin solution at room temperature and homogenized for 10 min with 
a high-shear mixer (Silverson L4R) set at 8000 rpm. Finally, the liquid was allowed to stand under 
static conditions for 8h to allow coacervate formation and phase separation. 
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4.2.3. Experimental design 
Several experiments were carried out to evaluate the influence of different ratios of water 
(g), maltodextrin (g) and Cremophor EL (g) in the amount of coacervate formed. A classical 
central composite design was applied. The design runs are listed in Table 1. Because interactions 
between the variables were expected, the following quadratic model was proposed in Eq. (1): 
Eq. (1)     Y = β0 + βiXi + βijXiXj+ βiiXi² 
where Y is the response, XiXj are the set points of the factors ‘i’ and ‘j’, respectively, in the 
mixture and β0, βi, βij and βii are the coefficients. 
The design points were chosen by the software (Design-Expert version 6.0.10, Stat-Ease 
Inc., Minneapolis, USA). Manual regression was performed. The significant highest order 
polynomial was selected without destroying the model hierarchy. Outlier-t limit was set at 3.5. 
The significant model was used for fitting the response. The lack-of-fit test and a normal 
probability plot of the residuals were performed in order to evaluate the model and to detect 
outliers. The models provide several comparative measures for model selection. R² statistics, 
which give a correlation between the experimental response and the predicted response, should 
be high for a particular model to be significant. Adjusted R², which gives a similar correlation 
after ignoring the insignificant model terms, should have good agreement with predicted R² for 
the model to be fit.  Predicted and adjusted R-squares should be within 0.20 of each other. 
Contour plots for the response were drawn for determination of the optimal variable settings. 
The response was the amount of coacervate formed. Equations in terms of actual factors: 
 
 
Coacervate (g) = -1.45544 + 0.00524 * A - 0.04747 * B + 0.04096 * C + 0.00024 * B² - 
0.000016 * B * C 
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Table 1: Design runs of the central composite design experiments and response results 
Run Factors Response 
 A:X1 Water 
(g) 
B:X2 Maltodextrin  
(g) 
C:X3 Cremophor®EL 
(g) 
Coacervate 
(g) 
1 
125 95 67.5 1.5 
2 150 70 35 1.2 
3 125 95 35 0.8 
4 150 95 67.5 1.6 
5 100 70 100 2.8 
6 100 120 100 2.0 
7 125 95 67.5 1.6 
8 125 95 67.5 1.6 
9 125 95 67.5 1.5 
10 150 120 35 0.8 
11 125 70 67.5 2.1 
12 150 70 100  2.2* 
13 100 95 67.5 1.5 
14 125 95 100 2.5 
15 125 95 67.5 1.5 
16 100 70 35 0.8 
17 125 95 67.5 1.4 
18 150 120 100 2.2 
19 125 120  67.5 1.5 
20 100 120 35 0.5 
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Analysis of variance of the response (Table 2) indicated that the response surface model 
developed for amount coacervate was significant, without significant lack of fit. In addition, the 
model summary statistics for the selected significant models were detailed (Table 2). It can be 
observed that for coacervate, R², predicted R² and adjusted R² were in good agreement, resulting 
in reliable models.  
 
Table 2: ANOVA – Influence of concentration the amount of water (g), 
 Maltodextrin c*01983 (g) and Cremophor
®
EL (g) on the response factors 
Response 
factor 
Model F-value Prob>F Lack of Fit  
F-value 
Prob>F 
Coacervate 153.17 <0.0001 1.71 0.2870 
 
St.dev. R² Adjusted R² Predicted R² 
Coacervate 0.09 0.9833 0.9769 0.9611 
 
4.2.4. Production of a solid dosage form via spray-drying 
 The two-phase liquid was again homogenized under high shear and spray-dried in a 
Mobile Minor spray-dryer (GEA Niro) using a two-fluid nozzle. The spray-dryer was operated in 
co-current flow at a constant inlet temperature of 130°C and an outlet temperature of 60°C. The 
liquid feed rate was 25 ml/min, controlled by a peristaltic pump. After spray-drying a free-
flowing powder was obtained.   
 
4.2.5. Production of a solid dosage form via granulation 
 The two-phase liquid was separated in an upper and lower phase. The upper phase was 
mixed in a 1:3.5 (w/w) ratio with tapioca dextrin in a mortar and allowed to dry at 40°C (to allow 
the residual water to evaporate). Finally, dry granules were obtained, indicating that the tapioca 
dextrin was capable of absorbing the liquid Cremophor®EL. 
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4.2.6. Characterization   
4.2.6.1. Fluorescence microscopy 
 Fluorescence microscopy was used to determine the distribution of the respective 
components in the respective phases during coacervate formation. For this purpose, the amount 
of material was down-scaled with a factor 10. Fluorescent labeling of the febantel/Cremophor® 
EL phase was performed by addition of 1 µL of a 10 mg/mL rhodamine B octadecyl ester 
solution in ethanol, after complete dissolution of the febantel in the Cremophor®EL. The liquid 
was thoroughly vortexed to ensure homogeneous distribution of the fluorescent dye. The 
aqueous maltodextrin phase was fluorescently labeled by addition of 10 µL of a 1 mg/mL FITC-
dextran solution in water. The liquid was thoroughly vortexed to ensure homogeneous 
distribution of the fluorescent dye. The formation of the coacervate was performed as described 
in section 4.2.2. Fluorescence microscopy images were recorded on Leica DM2500P microscope 
equipped with 10 x and 63x oil immersion objectives and a DFC360FX CCD camera. Hot stage 
microscopy was performed on the same microscope, but then equipped with a THMS600 heating 
stage. 
 
4.2.6.2.1H-NMR spectroscopy 
 1H-NMR spectra were recorded separately in D2O and/or MeOH-d4, depending on the 
solubility in the respective solvent of the components of interest. The 1H NMR spectra were 
recorded on a 300 MHz Varian Inova spectrometer. Spectra were acquired with a 90° pulse of 5 
s, a spectral width of 4500 Hz, an acquisition time of 5s, a preparation delay of 7s and 100 
accumulations. The chemical shift axis was calibrated by means of the D2O resonance at 4.72 
ppm from tetramethylsilane. 
 
4.2.6.3. X-ray diffractometry 
 X-ray diffractograms of the spray-dried powder and granules were recorded on a D5000 
Cu Kdiffractor (λ=0.154 nm) (Siemens, Karlsruhe, Germany) with a current of 40 mA in the 
angular range of 10° < 2θ < 60° using a step scan mode (step width 0.02°, counting time 1 
s/step). 
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4.2.7. In vitro drug release and stability 
 In vitro release of febantel from the respective formulation was evaluated using a VanKel 
VK7010 dissolution bath connected to a VK8000 automatic sampling station. Demineralized 
water (900ml) at room temperature (20±2°C) was used as dissolution medium. 5 mL samples 
were withdrawn after 5, 10, 15, 20, 30, 45 and 60 minutes and the febantel concentration was 
determined by measuring the UV-VIS absorbance at 280 nm using a Shimadzu UV-1650 PC 
spectrophotometer. 
To evaluate the effect of storage on the dissolution rate and solid state of the spray dried 
powder, the powder was stored for 6 months in sealed aluminum bags at different environmental 
conditions (25°C/ 60% RH, and 40°C/75% RH). Afterwards effect of the storage on the in vitro 
release kinetics of febantel was assessed as described above. 
Evaluation in a drinking water system for live stock (Figure 2) was performed to 
compare the spray-dried powder with the commercial febantel formulation Rintal (granules 
containing 10% febantel, Bayer), regarding their ability to provide a constant febantel level in the 
drinking water. Therefore, 8.12 g of spray dried powder, containing 950 mg of febantel, and 9.5 g 
of Rintal granules, also containing 950 mg of febantel, were added to a 250 L drinking water 
reservoir and allowed to dissolve for 10 min. Subsequently, the valve between the reservoir and 
the piping system, that connect the drinking nipples, was opened and samples were taken from 
the drinking nipples every 15 min for a period of 6h and analyzed for their febantel content by 
UV-VIS spectrophotometry. 
 
Figure 2: (A) drinking water system used in drinking water medication, (B) detail of the homogenization system. (C) 
PVC tubing, (D) drinking nipple. 
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4.2.8. In vivo evaluation 
The bioavailability of febantel in the spray dried formulation and in Rintal as reference 
formulation was evaluated in pigs (n=6, body weight 20-30 kg, age ±9 weeks). The study was 
approved by the Ethical Committee of the Faculty of Veterinary Medicine (Ghent University). 
The animals were individually housed in the live stock facilities of the Faculty of Veterinary 
Medicine at Ghent University. After one week acclimatization the trial was conducted as a cross-
over design with a 1 week wash-out period. All animals were weighed individually one day before 
administration of the formulation. A dose of 5 mg febantel per kg bodyweight was orally 
administered to the pigs. Therefore, the required amount of spray-dried powder (or Rintal 
granules) was added to 50ml water and then administered via a canule into the pig’s stomach. A 
volume of 50ml of water was used to rinse the canule. During drug administration the animals 
were immobilized. 
Blood samples were taken via the vena jugularis using a Venoject® system. A blood 
sample (3-5ml) was taken prior to each treatment and 0.5, 1, 2, 4, 8, 12, 24, 32 hours after 
administration of the febantel formulations. After sampling, the blood was centrifuged (4°C, 
800gn, 10 min) to separate the plasma. After centrifugation, the supernatant was transferred into 
another test tube and frozen at -18 °C.  
The plasma concentrations of both febantel metabolites (fenbendazol and oxfendazole) 
were determined using two separate HPLC methods developed [3]. The samples were prepared 
as follow: 40µL of the internal standard solution containing 10µl/mL of flubendazol (Janssen 
Pharmaceutica, Beerse, Belgium) in dimethylacetamide and 40µL of a 0.1M ZnSO4 solution were 
added to 150µL of plasma sample (mixed for 2 minutes centrifuged 1500gn for 3min). A 50µL 
aliquot of supernatant was injected (automatic injection system type L-7200, Hitachi, Tokyo, 
Japan) and eluted white a mobile phase consisting of an aqueous buffer (0.01M citric acid 
anhydrous and 0.004M disodium hydrogenium phosphate) and acetonitrile 60/40 (v/v) for the 
elution of fenbendazol and a mobile phase consisting of an aqueous buffer (0.01M citric acid 
anhydrous and 0.004M disodium hydrogenium phosphate) and acetonitrile 72.5/27.5 (v/v) for 
the elution of oxfendazole. A reversed phase column (C-18, 5µm, 12.5cm x 4mm, Lichrocar 125-
4, Merck, Darmstadt, Germany) was used for both analyses. The pump (Type L-7100 Merck 
Hitachi, Tokyo, Japan) flow rate was 1.0ml/min at room temperature. The variable wavelength 
UV-detector (L-7400, Merck Hitachi, Tokyo, Japan) was set at 290nm. Calibration curves were 
performed using known concentrations of fenbendazol (Hoeschet, Brussels, Belgium), 
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oxfendazol (Syntex Research, Palo Alto, Ca, USA) and febantel in drug free plasma collected 
from pigs. 
Pharmacokinetic parameters (Tmax, Cmax and AUC0-t) were calculated using the Microsoft
® 
Excel based program Pk Functions  (Joel I. Usansky, PhD, Atul Desai, MS and Diane Tang-Liu, 
PhD, Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA 92606, USA) 
[4].  
4.3. RESULTS AND DISCUSSION 
4.3.1. Formation of a liquid febantel/Cremophor®EL phase 
A first key step in our formulation strategy was the dissolution of the poorly water-
soluble drug in a liquid surfactant phase. Therefore, febantel (Figure 1A) was dissolved in the 
liquid surfactant Cremophor®EL. Cremophor®EL is a non-ionic surfactant obtained by reacting 
ethylene oxide with the hydroxyl groups of castor oil, leading to the formation of poly(ethylene 
glycol) chains onto a hydrophobic backbone. It has an HLB value between 12 and 14 and a 
critical micelle concentration (CMC) of 0.02% [8]. Cremophor®EL was heated to 130°C under 
stirring, which is slightly above the melting point of febantel (i.e. 129 °C), followed by the 
addition of crystalline febantel powder under stirring. Note that thermal degradation of febantel 
only starts at 175 °C and thermal degradation of Cremophor®EL at 300°C. Visual observation 
allowed to determine that around 2.5 min was required to reach complete solubilization of 
febantel in Cremophor®EL. An additional 2 min stirring at 130 °C was performed to ensure 
homogenization of the liquid. Figure 3A1-3A2 depicts the dispersion of febantel in Cremophor® 
EL before and after heating. The experiment was repeated on a small scale and the behavior of 
the febantel was followed by hot stage microscopy under bright field and polarized light. As 
shown in Figure 3B, the crystalline febantel gradually dissolves in the Cremophor EL medium 
with no residual crystallinity remaining. 
The liquid febantel/Cremophor®EL formulation was stable over prolonged periods of 
time (48h) without drug precipitation to occur. However, when this liquid was poured in aqueous 
medium a translucent gel was formed that readily became opaque (Figure 3A3). Figure 3C 
shows optical microscopy images taken at 1 min time intervals of this gelation process. Drug 
precipitates were formed that gradually grow over time. The optical microscopy image in Figure 
3C4, recorded under polarized light, clearly demonstrated the crystalline nature of these 
precipitates. Most likely, upon contact with water the drug precipitation occurs faster than the 
formation of Cremophor®EL micelles that could stabilize the febantel in an amorphous state in 
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their hydrophobic cavities. As this will severely reduce the drug dissolution kinetics we sought to 
optimize our formulation further by transforming the Cremophor®EL into a micellar state before 
febantel precipitation occurs, thus allowing stabilization of the febantel upon contact of the 
febantel/Cremophor®EL solution with water. 
 
 
Figure 3.(A) Photographs of test tubes containing a (A1) febantel/Cremophor
®
EL suspension, (A2) 
febantel/Cremophor
®
EL solution obtained after heating at 130 °C during 2 min and (A3) gel obtained by addition 
of water to the febantel/Cremophor
®
EL solution. (B) Hot stage microscopy images taken at 1 min time intervals 
after reaching 130 °C under (B1) bright field and (B2) polarized light during the heating of the febantel/Cremophor
®
 
EL suspension. (C) Bright field microscopy images taken at 1 min intervals after the addition of water to the 
febantel/Cremophor
®
EL solution. Panel C4 was is identical to C3, but recorded under polarized light to evidence 
the presence of crystallinity in the formed precipitates. 
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4.3.2. Formation of a liquid coacervate 
To resolve the issue of instantaneous drug precipitation upon contact of the 
febantel/Cremophor®EL solution with water, we sought a way to delay the hydration kinetics of 
the febantel/Cremophor®EL phase. We reasoned that this would lead to a slow transformation 
of the Cremophor®EL to a micellar state which would give sufficient time to the febantel to be 
distributed in the hydrophobic micellar cavities [9-11]. To achieve this goal, we poured the 
febantel/Cremophor®EL solution into a concentrated (i.e. 30 % (w/w)) aqueous maltodextrin 
solution. It is known that at elevated concentration, aqueous solutions of macromolecular species 
(as are Cremophor®EL and maltodextrin) are immiscible and phase separate [12]. Therefore, we 
hypothesized that addition of an aqueous macromolecular phase would therefore prevent 
immediate dissolution of the Cremophor®EL, which is also a macromolecule, thus preventing 
instantaneous precipitation of febantel, but would rather slowly draw water to the 
Cremophor®EL phase, allowing micelles to form, stabilizing the febantel in amorphous state [13-
15]. 
As good water-soluble polymer maltodextrin (Figure 1B) was chosen because this 
component could in a subsequent formulation step serve as carrier material to obtain a solid 
dosage form after spray-drying by absorbing the Cremophor®EL. The febantel/Cremophor®EL 
solution was added to a 30 % (w/w) aqueous maltodextrin solution under vigorous stirring. 
Immediately an opaque liquid formed (Figure 4A1), although both maltodextrin and 
Cremophor®EL are both readily water-soluble. Optical microscopy revealed that the opacity of 
the liquid is due the formation of an emulsion and not due to precipitation of febantel. This 
clearly demonstrates that the presence of maltodextrin the aqueous phase prevents the 
Cremophor®EL to dissolve in the aqueous phase. When left to stand under static conditions, 
both phases demixed (Figure 4A2-4A3) and a translucent lower phase (+/- 35 % of the total 
volume) and a slightly opaque yellowish upper phase (+/- 65 % of the total volume) were 
formed. This two-layer system was stable over a period of several months without precipitation 
of febantel to occur. It is noteworthy that in absence of febantel a similar phase behavior was 
observed. Importantly, when the two-phase liquid is diluted in aqueous medium, a clear solution 
is readily obtained (Figure 4B) and no drug precipitation is observed. 
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Figure 4.Photographs of test tubes containing the mixture of febantel/Cremophor
®
EL with maltodextrin (A1) 
directly after mixing, (A2) after 2h of demixing, (A3) after complete demixing.(B) Photograph of after addition of 
water to the coacervate phase. 
 
In a next series of experiments, we aimed to investigate the constitution of both phases 
and the phenomena that play a role in their formation. Therefore, we spiked before mixing the 
febantel/Cremophor®EL and the aqueous maltodextrin phase, with a fluorescent dye. 
Rhodamine B octadecyl ester (red fluorophore) was used as hydrophobic dye and is expected to 
be distributed in the same phase as hydrophobic drug febantel while FITC-dextran (green 
fluorophore) was used as hydrophilic dye that is expected to be distributed in the same phase as 
the maltodextrin. Upon mixing of both phases, foam was formed (Figure 5A) which slowly 
phase-separated over time, similarly as described above for the non-fluorescent labeled sample. 
After 8h, two distinct phases were formed with the lower phase stained yellow and the upper 
phase stained red. This already gives a strong indication that the maltodextrin will be distributed 
in the lower phase while the febantel will be distributed on the upper phase.  
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Figure 5.(A)Photographs showing the unmixing of the two-phase system. The red color is due to rhodamine B 
octadecyl ester (i.e. a hydrophobic dye), staining the Cremophor
®
EL phase while the yellow color is due to FITC-
dextran (i.e a hydrophilic dye), staining the aqueous maltodextrin phase. The arrows on the images recorded after 2h 
and 8h represent the formation of the coacervate phase. (B-C)Optical microscopy images at low (10x; panels 1 and 
2) and high (63x; panels 3 and 4) magnification recorded in DIC (panels 1 and 3) and fluorescence (panels 2 and 4) 
mode, (B) immediately upon mixing of the febantel/Cremophor EL and maltodextrin phases and (C) after 8 h and 
re-homogenization of the system. 
 
To gain more insight into the formation of both phases, optical microscopy images were 
recorded immediately upon mixing of the febantel/Cremophor®EL and the maltodextrin phase, 
and after phase separation and re-homogenization. As shown in Figure 5B, immediately upon 
mixing of both phases an emulsion was formed with red fluorescent febantel/Cremophor®EL 
droplets being dispersed in a continuous green fluorescent maltodextrin phase. Within a short 
time, the red fluorescent febantel/Cremophor®EL droplets agglomerated, forming a new 
coacervate phase. This third phase likely originated from the hydration of the Cremophor®EL 
droplets by water that was transported from the aqueous maltodextrin phase to the 
febantel/Cremophor®EL phase. Subsequently, the larger coacervate droplets coagulated and 
formed the upper phase of a biphasic liquid (Figure 5C).  
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These observations indicated indeed that upon contact with the aqueous maltodextrin 
phase, the febantel/Cremophor®EL phase withdraws water from the aqueous maltodextrin 
phase. Subsequently, upon contact with the attracted water, the Cremophor®EL is expected to 
form a micellar phase, distributing the febantel in the hydrophobic domains of the micelles. To 
confirm this hypothesis we analysed the composition of the lower and upper phase by 1H-NMR 
spectroscopy. Therefore, the two-phase system was prepared using deuterated water (D2O) 
instead of H2O. Figure6 shows the NMR spectra of the upper (Figure 6A) and lower phase 
(Figure 6B) as well as the spectra of the individual components. As febantel is poorly water-
soluble, but soluble in methanol, and maltodextrin is soluble in water but not in methanol we 
recorded the 1H-NMR spectra of the upper and the lower phase both in deuterated water (D2O) 
and in deuterated methanol (d4-MeOH). This should allow us to detect e.g. febantel in the most 
hydrated phase and maltodextrin in the least hydrated phase. From the data in Figure 6, it is 
clear that the upper phase contained quasi all Cremophor®EL and febantel while no Cremophor® 
EL and febantel was detected in the lower phase. Furthermore, maltodextrin was abundantly 
present in the low phase but also to a limited extent in the upper phase. Also D2O was observed 
in the spectrum of the upper phase that was recorded in d4-MeOH, this attributed to the 
hypothesis that the Cremophor®EL was present in a micellar state with the febantel solubilized in 
the hydrophobic micellar domains.  
Due to the detection limit of NMR spectroscopy, UV-VIS spectroscopy was used to 
determine the febantel concentration in the respective phases. We found that 59.4 g (i.e. 99 % of 
the initial amount of febantel) was present in the upper phase, supporting our NMR 
observations. Next, we aimed to assess whether Cremophor®EL is present in the upper phase as 
jammed micelles orienting their hydrophilic domains to a thin continuous water phase that 
surrounds the micelles or contrary, that the Cremophor®EL is present as inverted micelles with 
their hydrophilic domains oriented inwards. In the latter case, the febantel would be distributed 
in what could be considered as the continuous phase. We isolated the upper coacervate phase 
prepared with tap water and measured the conductivity of this phase, as commonly performed to 
determine the oil-in-water/water-in-oil nature of emulsions. From the value of 1.4 mS (vs. 0.3 mS 
for an water-in-oil emulsion of silicon oil in tap water, stabilized by Cremophor®EL) is clear that 
Cremophor®EL is present in micellar state with the hydrophilic domains oriented towards a 
continuous aqueous phase.  
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Figure 6.1H-NMR spectra of the upper and lower phase of the biphasic liquid recorded in respectively deuterated 
methanol (MeOH-d4) and deuterated water (D2O). To allow proper comparative analysis, the spectra of the single 
components are colored. 
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Figure 6 (Cont.).1H-NMR spectra of the upper and lower phase of the biphasic liquid recorded in respectively 
deuterated methanol (MeOH-d4) and deuterated water (D2O). To allow proper comparative analysis, the spectra of 
the single components are colored. 
 
The above-mentioned observations allowed us to postulate a model for the formation of 
the coacervate as schematically shown in Figure 7. First, upon addition of the 
febantel/Cremophor®EL solution to the aqueous maltodextrin solution, an emulsion is formed 
with febantel/Cremophor®EL as discrete phase and maltodextrin/water as continuous phase. 
Subsequently, over time water is drawn through osmosis in the febantel/Cremophor®EL droplets 
that also coagulate and form an upper phase. Meanwhile, the Cremophor®EL molecules orient as 
micelles and keep the febantel dissolved in their hydrophobic cavity. These micelles are 
presumably in a jammed state, surrounded by a thin water layer that also contains a relatively 
small amount of maltodextrin. 
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Figure 7.Schematic representation of the formation of the two-phase liquid with the upper liquid being a coacervate 
phase. 
 
To assess the influence of the water, maltodextrin and Cremophor®EL concentration on 
the amount of coacervate formed, an experimental design was performed.  
 
 
 
Figure 8. 3D surface plots showing the effect of the amount of water (g), maltodextrin (g) and Cremophor
®
EL (g) 
in the quantity of obtained coacervate phase (g). 
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Figure 8 (Cont). 3D surface plots showing the effect of the amount of water (g), maltodextrin (g) and Cremophor 
®EL (g) in the quantity of obtained coacervate phase (g). 
 
The resulting density plots are shown in Figure 8 and indicate that the concentration of 
Cremophor®EL is the main factor determining the amount of coacervate phase that is formed.  
 
4.3.3. Transformation into a solid dosage form and in vitro release kinetics 
A third and final step in our formulation strategy was the transformation of the liquid 
phase into a solid form. Therefore, two routes were pursued (1) spray-drying of the homogenized 
two-phase system and (2) granulation using the upper coacervate phase. In the first strategy, 
maltodextrin played a role as carrier, intended to absorb the liquid Cremophor®EL upon 
evaporation of the water. In the case of granulation, tapioca dextrin was used as absorbing carrier 
material to obtain solid granules. To analyze whether these approaches allowed retaining the 
febantel in an amorphous state, X-ray diffraction was performed on the spray-dried powder and 
the granules. Figure 9 shows the X-ray diffractograms of the crude components. Whereas 
febantel is highly crystalline, the produced solid dosage forms, either via spray-drying or 
granulation, completely lacked the crystalline peaks, indicating that upon processing into solid 
form, febantel was retained in amorphous state.  
 
CHAPTER 4 - Formulation of Poorly Water- Soluble Drugs via Melt- Coacervation   
- 104 - 
 
Figure 9: (A) X-Ray diffractograms of febantel, tapioca dextrin and febantel formulated by granulation of the upper 
coacervate phase with tapioca dextrin. (B) X-Ray diffractograms of febantel, maltodextrin and febantel formulated 
by the homogenized two-phase liquid. 
 
 Subsequently, in vitro drug release kinetics were investigated in dissolution vessels at room 
temperature and compared to Rintal and a physical mixture of the respective components. Rintal 
is a commercial febantel formulation consisting of granules that contain a drug load of 10% 
formulated with sodium docusate and saccharine. As shown by the cumulative release curves in 
Figure 10A, drug release from both the spray dried powder and the tapioca dextrin granules was 
fast and complete compared to the physical mixture and Rintal. The poor performance of Rintal 
in this experimental in vitro set-up is likely due to the crystalline state of the febantel within this 
formulation whereas the febantel in our coacervate-based formulation is in amorphous state. 
 Formulations containing amorphous drug are inherently prone to drug recrystallization. 
Therefore, we evaluated the long-term stability of the spray-dried powder. The powder was filled 
in sealed aluminium bags and stored at either 25°C (relative humidity (RH) of 60%) and 40°C 
(relative humidity (RH) of 75%). As shown in Figure 10B, drug release kinetics were not 
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influenced by this long period of storage. Furthermore, we recorded the X-ray diffractograms of 
the respective samples and no crystalline peaks could be detected. These data indicated that the 
formulation successfully retains febantel in amorphous state for prolonged periods of time. 
 
 
 
Figure 10. (A) Cumulative febantel release from the spray-dried and granulate formulations. As control 
formulations, we used a physical mixture of the components as well as a commercial febantel formulation (i.e. Rintal) 
(B)Cumulative febantel release curves before and after storage for 6 months at constant temperature and relative 
humidity. 
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4.3.4. Evaluation of the formulation for drinking water medication  
 For application in drinking water medication, it is essential that upon addition of the 
formulation to the drinking water reservoir it readily distributes over the entire reservoir, allowing 
constant febantel levels to reach the drinking nipples. Therefore, a series of experiments were 
performed to compare the spray-dried powder formulation with the commercial Rintal 
formulation. Both formulations were added to a drinking water reservoir and after 10 min 
(allowing the formulation to dissolve/disintegrate), non filtered samples were withdrawn from 
the drinking nipples at regular time intervals and analyzed for their febantel content. As shown in 
Figure 11, the spray-dried formulation provided a quasi-constant drug level over a period of 6 
hours. Contrary, large alterations in drug levels were observed for the Rintal formulation. This is 
likely due to the presence of non-water soluble granules, leading to inhomogeneous drug 
distribution in the drinking water reservoir. 
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Figure 11: Febantel levels over time at the drinking water nipples 10 minutes after the addition of respectively the 
spray-dried formulation and Rintal to the drinking water reservoir. 100 % drug corresponds to the theoretical 
maximum of febantel that can be released in the drinking water reservoir upon complete dissolution of febantel. 
 
4.3.5. In vivo evaluation  
Pigs received either the spray dried powder formulation or the commercial Rintal 
reference formulation, in both cases at a dose of 5 mg of febantel per kg bodyweight. The 
formulations were first dispersed in water and administered via a canule directly into the stomach 
of the animals. Subsequently, blood samples were withdrawn at regular time intervals and 
analyzed for the respective metabolites of febantel, being febendazole and oxfedazole. 
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The individual maximal plasma concentrations (Cmax) and the area under the curve 
(AUC)-values are shown in Table 3 and the concentration of the metabolites over time in blood 
samples shown in Figure 12. Statistical analysis revealed no significant difference between the 
Tmax, Cmax and AUC0-t levels of the spray-dried formulation and Rintal. For fenbendazole the mean 
difference between the formulations was 90 (95% CI -400 to 220) and for oxfendazole the mean 
difference between the spray-dried formulation and Rintal was 829 (95% CI -849 to 2507), while 
the median change in Tmax values for oxfendazol and fenbendazol between the spray dried 
formulation and Rintal was not significantly different from 0 (i.e. respectively 0.141 and 0.236). 
 
Table 3: Statistical evaluation of pharmacokinetic parameters (Tmax, Cmax and AUC0-t) of the metabolites 
fenbendazole (Fen) and oxfendazole (Oxf) in blood plasma. 
 
Drug 
metabolite 
spray dried 
formulation (µg/L) 
Rintal 
(µg/L) 
95% CI 
 
Mean SD Mean SD Mean 
dif. 
Lower Upper p-value 
AUC0- 
Fen 645 229 735 204 -90 -400 220 0.4644 
Oxf 5655 1553 4826 837 829 -849 2507 0.2419 
Cmax 
Fen 143 77 61 3 82 -28 191 0.1064 
Oxf 424 137 276 44 148 -20 316 0.0705 
          
  Media
n 
Min.- 
Max. 
Median Min. - Max. 
Nonparametric 
Wilcoxon signed rank 
test p-value 
Tmax 
Fen 4 2-8 6       4-12 0.236 
Oxf 0.5 0.5-4 2       2-8 0.141 
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Figure 12: Plasma concentration profiles for both febantel metabolites (fenbendazole and oxfendazole) after 
administration of respectively the spray-dried formulation and Rintal. 
 
4.4. Conclusions 
 
 In this work we have introduced drug melting in a liquid surfactant, followed by the 
formation of a coacervate, as an attractive route to dramatically enhance the dissolution kinetics 
of poorly water-soluble drugs. Febantel, a crystalline drug to treat helminthic infections in 
livestock was used as model drug. In a first step, febantel was dissolved in Cremophor®EL, a 
non-ionic liquid surfactant, and subsequently poured into a concentrated aqueous maltodextrin 
solution. The presence of maltodextrin avoided instantaneous precipitation of the febantel and 
induced the formation of a coacervate phase comprising highly concentrated Cremophor®EL 
micelles. These micelles stabilized the febantel, avoiding recrystallization. Subsequently, the 
obtained two-phase liquid was further processed into a solid form via either spray-drying or 
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granulation. Compared to crude febantel and Rintal (a commercial febantel formulation), the 
formulations produced via coacervation exhibited a dramatic increase in vitro dissolution kinetics. 
Finally, we demonstrated in a realistic veterinary setting, comprising a drinking water reservoir 
connected to drinking nipples, that the coacervate formulation yielded constant drug levels at the 
drinking nipples, which was found not to be the case for the commercial Rintal formulation. A 
first in vivo evaluation did not indicate significant differences in pharmacokinetic parameters 
between the spray dried formulation and the Rintal reference formulation. However, these 
experiments were performed by direct administration of the formulations into the stomach of 
pigs, while more extensive studies are required, involving administration to the formulations to 
the drinking water reservoirs, to obtain a clear and conclusive view on the potential of the 
developed formulation strategy. 
 In conclusion, these data showed that the coacervation formulation strategy shows 
promise for mass drinking water medication. Furthermore, as the formulation can easily be 
transformed into a solid state, it also holds potential for further development towards solid 
dosage forms for oral intake. 
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One of the major causes of new drug molecules failing to reach the market is poor 
bioavailability. The introduction of the Biopharmaceutical Classification System (BCS) has 
provided a basis to categorize drugs based on the two major parameters affecting absorption, 
being solubility and permeability. Several techniques have been developed to enhance the 
absorption and bioavailability of poorly soluble and poorly permeable drugs based on the BCS 
concept. Molecules with poor solubility frequently referred to as BCS Class II (poorly soluble) 
and Class IV (poor solubility and permeability), possess insufficient aqueous solubility to allow 
adequate and consistent gastrointestinal absorption ensuring pharmacological effect, and thereby 
pose additional challenges to drug formulation scientists. 
 Chapter I gives an overview of the current options available to the formulation scientist 
to improve the bioavailability of BCS Class II and IV drugs. The majority of the formulation 
techniques described in this chapter takes advantage of the higher drug solubility in organic 
solvents to transform the drug compounds into a high-energy amorphous state or into small size 
crystalline particles in order to significantly enhance drug solubility. However, the use of organic 
solvents in drug formulation to overcome poor aqueous solubility of drugs has an important 
drawback. It is unrealistic to assume that organic solvents can be completely eliminated from the 
final drug product. Usually some small amounts of solvents may remain in the final product, 
which raises concerns regarding their in vivo toxicity and effect on the physicochemical stability 
of the active compound. Therefore, this PhD thesis aimed to evaluate different approaches to 
formulate poorly water- soluble drugs without the use of organic solvents. 
Chapter 2 describes a first approach to the drug-solubility issue by formulating the 
poorly water-soluble drug carbamazepine into tablets, intended for oral intake, with a self-
emulsifying excipient to increase drug dissolution. For this purpose, Gelucire ®44/14 was chosen 
as previous work reporting on the use of Gelucire®44/14 as excipient in drug formulation 
highlighted its capability to enhance drug dissolution but also mentioned difficulties to formulate 
Gelucire 44/14 based formulations into immediate-release tablets for oral intake. Due to its low 
melting point and waxy behavior, Gelucire®44/14 acts as a binder, thereby strongly increasing the 
disintegration time of tablets produced via compression. 
 In the pursuit of an immediate release tablet formulation, carbamazepine was first 
processed with Gelucire®44/14 via either granulation or spray drying and subsequently 
compressed into tablets. Compression was observed to strongly decrease drug dissolution, 
relative to the non-tableted granules and spray-dried powder. This could be attributed to the 
relatively long disintegration time of the tablets. To address this issue, super disintegrating 
excipients were added to the formulations. Unfortunately, these did not accelerate drug 
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dissolution since no significant effect on tablet disintegration was observed. Likely this has to be 
attributed to the binding capacity of Gelucire®44/14. However, fast and complete tablet 
disintegration was obtained by incorporation of an effervescent mixture in the formulation. In 
this case tablet disintegration and full drug dissolution was reached within 15 min, thus 
presenting a suitable immediate release formulation for the poorly water-soluble drug 
carbamazepine. 
Chapter 3 focused on the formulation of drugs (i.e. itraconazole and febantel) with an 
even lower water-solubility for which the formulation approach, developed in Chapter 2, is 
insufficient. To formulate these drugs, we aimed to produce micro- and nanocrystalline 
suspensions containing Gelucire®44/14 as additional solubility enhancement agent. For this 
purpose, two top down and one bottom up approach were developed. The top down approaches 
involved either ball milling or ultrasound treatment, both in the presence of Gelucire®44/14, to 
reduce the size of existing drug crystals. Both techniques allowed to significantly reduce the size 
of the drug crystals, with ultrasound treatment being the most powerful method. Both methods 
also allow to enhance the dissolution of febantel with the ultrasound treated formulation 
providing the best dissolution. In case of itraconazole, no influence of both processing 
techniques was observed, which is likely to be attributed to its even lower water solubility. 
In the bottom up approach, itraconazole and febantel nanosuspensions were produced by 
dissolving the drug in molten Gelucire®44/14. This molten mixture was atomized into cold 
water. During the atomization, cavitation was induced by ultrasonication. This process yielded 
milky suspensions in the submicrometer range. Furthermore a fraction of the drug was found to 
be in amorphous state. The nanosuspensions of both drugs showed enhanced dissolution. In case 
of febantel drug dissolution was superior to the formulations produced via ball billing or 
sonication, while in case of itraconazole drug dissolution was obtained, which was not the case 
for any of the other formulations.  
Chapter 4 describes a melt-coacervation technique for the formulation of febantel 
intended for mass drink water medication for veterinary purposes. In this regard it is 
advantageous to obtain a solid formulation, as this would not only avoid stability issues related to 
nanosuspensions, but also offers benefits regarding easy transport, storage and dosing. In a first 
step in the melt-coacervation approach, febantel was dissolved in liquid micelle-forming 
surfactant (i.e. Cremophor®EL) under heating. Next, the liquid was added to an aqueous 
maltodextrin solution under high shear homogenization. Spontaneously, a coacervate is formed, 
comprising a maltodextrin rich phase and a Cremophor®EL rich micellar phase, with the febantel 
being distributed within the hydrophobic core of the Cremophor®EL micelles. This phenomenon 
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is due to the incompatibility between concentrated aqueous solutions of maltodextrin and 
Cremophor®EL. Further processing via spray drying yielded a dry powder as the excess of 
maltodextrin was able absorb the liquid Cremophor®EL phase. Alternatively, a dry formulation 
could also be obtained by granulation of the Cremophor EL rich phase as granulation liquid and 
tapioca dextrin as solid carrier. Importantly, X-ray diffraction elucidated that both techniques 
allowed retaining febantel in amorphous state. Drug dissolution was found to be fast and 
complete, with the spray dried formulation performing the best. The spray-dried formulation 
showed long-term stability and could provide constant drug levels in a drinking water system, 
whereas large drug fluctuations were observed for the commercial Rintal formulation. 
Preliminary in vivo studies in pigs, further demonstrated the potential of the melt-coacervation 
technique. 
 Summarizing, this PhD thesis explores several solvent-free approaches to enhance the 
dissolution of poorly water-soluble drugs. For this purpose it was found essential to use bio-
compatible surface-active agents and to reduce the particle size of the drug crystals. Especially the 
formation of drug crystals in the nano-range was found to be a potent strategy to enhance drug 
dissolution. These nanosuspensions, however, are prone to re-agglomeration of drugs 
nanocrystals and further research is required to allow transformation to solid formulation. In this 
regard it will be essential to assure that upon redispersion in water again stable nanoparticles are 
generated, to allow obtaining enhanced drug levels in vivo.  
Furthermore, methods that yield drug in an amorphous are also potent enhancers of drug 
dissolution. In this regard, further research is required on long-term stability of the amorphous 
state. Also it is yet unknown whether results obtained via a specific formulation technique for 
one type of drug can be translated to other drug molecules as well. 
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